US 20160022579A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0022579 A1 Siegfried (43) Pub. Date: Jan. 28, 2016

(54) LIQUID COMPOSITIONS CAPABLE OF A619/00 (2006.01) FOAMING AND INCLUDING ACTIVE A63L/96 (2006.01) AGENTS, AND METHODS FOR MAKING OR A613 L/474 (2006.01) DEVELOPNG SAME A613 L/7048 (2006.01) A63L/92 (2006.01) (71) Applicant: MIKA Pharma GmbH A 6LX3/573 (2006.01) (52) U.S. Cl. (72) Inventor: Bernd G. Siegfried, Limburgerhof (DE) CPC ...... A61K 9/122 (2013.01); A61 K31/192 (2013.01); A61 K3I/I67 (2013.01); A61 K (21) Appl. No.: 14/633,929 31/573 (2013.01); A61K 31/196 (2013.01); A61K 31/4174 (2013.01); A61 K3I/7048 (22) Filed: Feb. 27, 2015 (2013.01); A61 K9/0014 (2013.01) Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 12/838.737, filed on A liquid composition Suitable for topical use comprising is Jul. 19, 2010, now Pat. No. 9,005,626. provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active (30) Foreign Application Priority Data agent; wherein the liquid composition is capable of mechani cally foaming without an additional propellant; and wherein Jul. 24, 2009 (DE) ...... 10-2009-034-603.1 upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam Volume of at least about 400 ml Publication Classification and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as (51) Int. Cl. determined using a SITA foam measurement. Also provided A6 IK 9/12 (2006.01) herein are methods of making disclosed compositions and A6 IK3I/67 (2006.01) methods of use. Patent Application Publication Jan. 28, 2016 Sheet 1 of 19 US 2016/0022579 A1

12OO

1 OOO

Mam-m-m-m-MYu-a-wave-m---saw-aw-al------was 5 600 -- 1st measurement -- 2nd measurement -- 3rd measurement > w-r-marsaw-awaamhormoxamin-a------Hermaxx-x-xx-x-x---winnu-mi 400 ------...------.... t i S. 2001 - ---

O ------s ------O.O. 5.0 10.0 15.0 2O.O 25.O 300 35.0 time (min) Figure 1 Patent Application Publication Jan. 28, 2016 Sheet 2 of 19 US 2016/0022579 A1

1000 ------1st measurement -- 2nd measurement 800 -- 3rd measurement

6 OO

4 O O

200 ------

------3. cap.m.a.s. Im. ------OO 5.0 10.0 15.0 2O.O 25.0 30.O 35.0 time (min) Figure 2 Patent Application Publication Jan. 28, 2016 Sheet 3 of 19 US 2016/0022579 A1

1200

1000

800

6 OO --- 1st measurement | - 2nd measurement 4 O O -H------m-m-m-m-ul------m-mw------umu ------. -- 3rd measurement

2 OO

------f r 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 time (min) Figure 3 Patent Application Publication Jan. 28, 2016 Sheet 4 of 19 US 2016/0022579 A1

1200 - ---

1000 --- or ------

800

S. ------600 ------1st measurement 5 - 2nd measurement O 400 ------3rd measurement s S 200 ------

O ------... -- r --- O.O 5.O 1O.O 150 200 25 O 30.0 35.0 time (min) Figure 4 Patent Application Publication Jan. 28, 2016 Sheet 5 of 19 US 2016/0022579 A1

1200

1 OOO

800

6O O St n ea S. t re n e n t -- 2nd measurement ... 3rd measurement 4.O O

200

O.O 5.0 OO 150 2O.O 250 30.0 350 time (min) Figure 5 Patent Application Publication Jan. 28, 2016 Sheet 6 of 19 US 2016/0022579 A1

1200 --

1 OOO ------

800 || -- 1st measurement -- 2nd measurement S ... 3rd measurement a 600 - - T" ...------vmm-mm-um-m-m-m-m-ul S E 9 S its S.

200 - - - -m-m-m------w

0 - s ------...... r -----...- O.O 5.O 10.0 15.O 2O.O 25.0 3OO 35.0 time (min) Figure 6 Patent Application Publication Jan. 28, 2016 Sheet 7 of 19 US 2016/0022579 A1

1200 WWWWSSM

1 OOO now------

800

600 ------or " -- 1st measurement 5 -o-, 2nd measurement O 400 --- -- 3rd measurement s S.

200 v-M- M------M.

O ...un-----or- - error- r OO 5.O 10.0 150 200 250 30.0 350 time (min) Figure 7 Patent Application Publication Jan. 28, 2016 Sheet 8 of 19 US 2016/0022579 A1

1200

1000 -

800 : ------

S www.www.'xw8wimmwww.c. 600 ------" " -- 1st reasurement -- 2nd measurement 9 -- 3rd measurement a 400 ------s S. 200 | ------

O -or- ---. " O.O 5.O 10.0 15.0 200 25.0 300 350 time (min) Figure 8 Patent Application Publication Jan. 28, 2016 Sheet 9 of 19 US 2016/0022579 A1

1200 -

1 OOO

800 ------...-a------e-r-sorror----useu------, - 1st eaS feet -- 2nd measurement E | -- 3rd reasurement a 600 ------e.------r------m------E Eg E 400 --- ets S

2OO u...w....------m ------

O 0.0 5.O 10.0 15.0 2O.O 250 3O.O 350 time (min) Figure 9 Patent Application Publication Jan. 28, 2016 Sheet 10 of 19 US 2016/0022579 A1

g 800 – ---- ... -- 1st measurement o -- 2nd measurement 2E 600 | -- 3rdric reasurement g ------400 ------S.

200 ------M

O ar ------or-cro-or-n- 0.0 5.0 10.0 15.0 20.0 25.0 30.0 350 time (min) Figure 10 Patent Application Publication Jan. 28, 2016 Sheet 11 of 19 US 2016/0022579 A1

1200 ---. ------

1000 ------MM ... -----

800

E 600 ------um-----m------:rum-ric-owner-winner-writtan...a...s.l...a...covar. --- 1st measurement s -a- 2nd measurement g -- 3rd measurement 400 +- m-m-m- --- s S. 200

O - } : ------0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 time (min) Figure 11 Patent Application Publication Jan. 28, 2016 Sheet 12 of 19 US 2016/0022579 A1

1200 .

1000 —- -- 1st measurement | -- 2nd measurement

800 ------or--or | ---- 3rdouMW&W-WWW-WWWW-8wm-W-WWWrwoxwmwmw-vom measurement

E 600 m'W SSM MMM v. M' S st EEs is ESE=E. S. . . . . g E 400 - - es S 200

O ~rom s - : O.O 5.0 1.O.O 15.O 200 25.O 3OO 35.O time (min) Figure 12 Patent Application Publication Jan. 28, 2016 Sheet 13 of 19 US 2016/0022579 A1

1200 ---—- - - -—------—---

1OOO

600 ir-r- . 1st measurement - 2nd measurement 400 -- 3rd measurement

2OO

car---...------— — — -r-sna. 50 1 OO 150 2O.O 25.O 3OO 35.O time (min) Figure 13 Patent Application Publication Jan. 28, 2016 Sheet 14 of 19 US 2016/0022579 A1

1200 ------

1000 - -

800 ------1st measurement --a | -- 2nd measurement -- 3rd measurement Sc. 600 ------... --- c) E 2 9 400 (vs. ------200 ------m ------s------...W------

O ------r T -- run-- : 0.0 50 10.0 150 200 25.0 30.0 35.0 time (min) Figure 14 Patent Application Publication Jan. 28, 2016 Sheet 15 of 19 US 2016/0022579 A1

12OO ------

1OOO l ---- res-Ferra ara-a-a====Es==ss-seas-s-s-s-s-s-s-s------

8OO --- mmM ------M - Mammam - M.

5 | ------M.--...------armw 600 mm M. maa SMWM -- 1st measurement ----, 2nd measurer ent E 400 - -- 3rd measurement t S 200 -

O | : O.O 5.O 1O.O 15.O 2O.O 25.O 3OO 350 time (min) Figure 15 Patent Application Publication Jan. 28, 2016 Sheet 16 of 19 US 2016/0022579 A1

1200

1OOO

800 - 2 E 600 - - wo-wrim-X-rw-w-X-rm------xx-cc-awww.twin-ex-xx-xx-x------.- - - 1st measurement 5 | -- 2nd measurement aO 400 - ----. 3rd measurement s S

2OO mmM

O - I p-r- OO 5.O 1O.O 15.O 2O.O 250 3O.O 35.O time (min) Figure 16 Patent Application Publication Jan. 28, 2016 Sheet 17 of 19 US 2016/0022579 A1

1200

1000 ------m-m-m-m-m-m-

800 1. 600 ------1st measurement 5 -- 2nd reasurement g -- 3rd measurement E 400 ------4th measurement (ts S. -- 5th measurement 200 wuwassetesveterosoretirestro-o-o-o-wross-orie,---

0 - for- I 0.0 5.0 10.0 15.O 2O.O 250 3O.O 35.0 time (min) Figure 17 Patent Application Publication Jan. 28, 2016 Sheet 18 of 19 US 2016/0022579 A1

-- 1st measurement -as-, 2nd measurement -- 3rd measurement 4O O - " ------or-o-

2OO

------...ru------0.0 5.0 10.0 150 20.0 25.0 30.0 35.0 time (min) Figure 18 Patent Application Publication Jan. 28, 2016 Sheet 19 of 19 US 2016/0022579 A1

1200 Tri------

1000 ------wom

800

5 film-m-m-m-m-on-count cy 600 - -e- 1st measurement 5 -a- 2nd measurement O 400 - 3rd measurement es S.

200 - -

O I ------...... --—------OO 5.O 10.0 15.0 2O.O 250 3OO 35.0 time (min) Figure 19 US 2016/0022579 A1 Jan. 28, 2016

LIQUID COMPOSITIONS CAPABLE OF maceutically active liquid and one then attempts to foam it by FOAMING AND INCLUDING ACTIVE varying the mechanical foaming technique, in particular, by AGENTS, AND METHODS FOR MAKING OR varying the air pressure, the geometry and configuration of DEVELOPING SAME the foam head and the valve of a particular foam applicator. However, such a development process for foamable, origi RELATED APPLICATION nally liquid, pharmaceutical compositions is very time inten sive and may suffer from a drawback such that a foam differ 0001. This application is a continuation of U.S. Ser. No. ing in composition and essentially inhomogeneous can result 12/838,737 filed Jul. 19, 2010, which claims priority to Ger from varying the configuration of the aforementioned param man patent application DE10-2009-034-603.1, filed Jul. 24. eters of the mechanical foam applicator. 2009, and hereby incorporated by reference in its entirety. 0007 Thus, one underlying problem of the present inven tion is to provide a method for the development of a liquid FIELD pharmaceutical composition to be applied as foam to the skin, 0002 The present disclosure is directed in part to a method by which the development time for such pharmaceutical com for making or developing liquid pharmaceutical composi positions is substantially simplified and shortened. Further, tions to be applied as a foam to the skin, and topically appli another underlying problem of the present invention is to cable compositions. provide a topically applicable composition that can be applied as foam and that contains a systemically or topically BACKGROUND acting pharmaceutical active ingredient, and, may be, for 0003 Topically applied pharmaceutical compositions that example, be developed by the disclosed processes. exist in the liquid state and are present as a foam when applied are familiar. For example, EP 0510561 B1 describes one SUMMARY such pharmaceutical composition applied as foam, wherein 0008 Provided herein is a liquid composition suitable for the basic liquid used in the known pharmaceutical composi topical use comprising: a phospholipid foaming agent and at tion is foamed exclusively by mechanical action. The basic least one solvent; a pharmaceutically acceptable active agent; liquid composition that is mechanically foamed contains, as wherein the liquid composition is capable of mechanically ingredients, a surfactant as the foaming agent, a solvent or foaming without an additional propellant; and wherein upon mixture of solvents, as well as a pharmaceutical active ingre mechanical foaming of 250 ml of the liquid composition dient, wherein this known liquid composition should be results in a foam with a foam volume of at least about 400 ml foamable simply by mechanical action, without the use of a (e.g., about 450 to about 1400 mL or about 600 mL to about propellant. In example 5 of EP 0510561 B1, one such known 1200 mL) and a foam stability wherein at least about 50% of composition is described, containing an aqueous alkylamido the foam volume is still present after about 5 minutes at 25° betaine solution as the surfactant. In addition, the composi C., (e.g., about 55% to about 85% of the foam volume is tion described in this example is provided with lecithin, present after 5 minutes, or about 85% to about 100% of the which serves solely to form liposomes. foam volume is still present after about 10 minute) as deter 0004. In order to be able to measure the foaming behavior mined e.g., using a SITA foam measurement. of liquid compositions, various measurement techniques are 0009. Also provided herein, in one embodiment, is a known and also standardized, such as by DIN Standard method for making a foamable liquid composition for topical 53902. The particular liquid composition being investigated use, comprising: a. providing a liquid composition compris is subjected to a more or less reproducible mechanical action ing at least one pharmaceutically active agent, at least one for a given time in order to create a foam, whose Volume and solvent, and a foaming agent; b. mechanically creating a foam stability are measured. According to DE 19740 095A, how of the liquid composition; c. scanning the foam surface to ever, known measurement techniques do not adequately dis determine the stability and the volume of the foam; d. Varying tinguish between the foam volumes and foam stabilities of the concentration of at least one of the pharmaceutically compositions which are similar in terms of their ingredients. active agent, the solvent, or the foaming agent; and e. repeat DE 19740 095 A proposes foaming the liquid composition ing steps band c, if needed, until 250 ml of the liquid com being measured by using a stirrer with a given profile, which position, after the mechanical creation of the foam, has a foam is driven at a given speed of rotation. The foam created in this volume of at least 400 mL and a foam stability wherein at least way is visually measured. about 50% of the foam volume is still present after about 5 0005. A further development of this foam measuring tech minutes at 25°C. nique is described in EP 1092970 B1, wherein the develop (0010. In a provided method of development of a liquid ment differs from the measurement technique previously pharmaceutical composition to be applied as a foam to the described in reference to DE 197 40 095 A by providing an skin, having as minimum components a solvent, a pharma automatic determination of the height of the foam via mea ceutical active ingredient, and a foaming agent, the method suring electrodes. This measurement method, which is called includes foam volume and the foam stability to be determined the “SITA measurement method in the present text, allows by a standardized SITA measurement method, wherein no one to determine the foam volume on the one hand, and on the propellant is used in this measurement method. For example, other hand the foam stability of liquids, especially dyeing and in a provided liquid pharmaceutical composition, the at least cleaning solutions, electroplating agents, emulsions, rinsing one foaming agent, the at least one solvent and the at least one agents, body care products or even beer, so as to obtain a pharmaceutical active ingredient are varied in regard to their quality rating of the aforementioned foamable liquids. chemical nature and/or concentration until the foam created 0006. When one needs to develop liquids that are foam by the SITA measurement method understandardized condi able and therefore are applied as a foam in the field of phar tions has a foam volume of at least 400 ml, especially a foam macy, it is usually proposed to proceed by selecting a phar volume between 450 and 1400 ml, and preferably a foam US 2016/0022579 A1 Jan. 28, 2016

Volume between 600 and 1200 ml. Furthermore, the foam developed according to the invented method. The term “and/ according to a method of the invention must have such a foam or used in the present specification means that all or some stability that it still has, after a dwell time of up to ten minutes elements of the particular listing are to be construed addi and especially after a dwell time of up to five minutes, at least tively or that some or all elements of the respective listing are 50% of the foam volume and especially between 55% and to be construed alternatively. Moreover, it should be stated 100% of the foam volume and preferably between 85% and that all terms used in the singular case in the present specifi 99% of the foam volume that was originally present imme cation of invention also include the plural of these terms. diately after the creation of the foam. In other words, there fore, the development method according to the invention calls BRIEF DESCRIPTION OF THE FIGURES for varying the minimum ingredients (solvent, pharmaceuti cal active ingredient, and foaming agent) contained in the 0014 FIGS. 1-16 depicts 3 measurements (as indicated in liquid pharmaceutical composition that is Supposed to form the legend) foam Volume in mL (y-axis) vs. time (minutes) for the foam when applied in terms of their chemical nature various compositions as described herein. and/or their concentration until they give rise to a foam by the 0015 FIG. 17 depicts 5 measurements (as indicated in the SITA measurement method under standardized conditions legend) foam Volume in mL (y-axis) vs. time (minutes) for the whose foam Volume possesses the previously quantified Vol composition described in Example 17, below. umes and whose foam stability possesses the previously 0016 FIGS. 18 and 19 depict 3 measurements (as indi quantified Stabilities. cated in the legend) of foam Volume in mL (y-axis) vs. time 0011. The above-described method of the invention has a (minutes) for various compositions as described herein. number of advantages. Thus, it has been established, Surpris ingly, that the method of the invention enables an especially DETAILED DESCRIPTION easy and rapid development of Such liquid pharmaceutical compositions as can be reproducibly foamed with a number 0017. In an embodiment, disclosed methods relate to of foam applicators, so that unlike the prior art described at method of development of a liquid pharmaceutical composi the outset one can develop pharmaceutical foams that are tion to be applied as a foam to the skin calls that include especially reproducible in terms of their foam consistency producing a correlation between the foam as specified by the and their foam composition. For example, if the goal of Such SITA measurement method and the desired pharmaceutical a development is to provide a liquid composition whose foam properties. By desired pharmaceutical properties is meant in should have a relatively short stability after being foamed by particular the transport of active ingredient through the layers means of a Suitable mechanical foam applicator, so that it of the foam into and/or through the skin, i.e., the permeation quickly breaks down after being applied to the skin, in the and/or penetration of the skin and/or the fine distribution of method of the invention one will vary the chemical nature the active ingredient and/or the resulting pharmaceutical and/or the concentration of the ingredients until a foam effect. For example, if a goal of the development in the results in the SITA measurement method whose foam stabil method of the invention is, for example, that the active ingre ity is distinguished in that, within two to four minutes, the dient should quickly get onto the skin Surface in relatively foam volume still takes on a value between 50% and 70% of high concentration, one will vary the nature and/or concen the original foam Volume. In contrast, when the objective is to tration of the ingredients in the liquid composition being create an especially stable foam, the chemical nature and/or foamed by the SITA measurement method so that the result the concentration of the minimum ingredients of the liquid ing foam has a relatively small foam Volume, especially a composition which afterwards forms the foam will be varied foam volume between 450 ml and 600 ml, and a relatively low so that a foam results whose foam stability is so high that after foam stability, especially a foam stability after five minutes eight to ten minutes there is still present between 85% and between 55% and 70% of the foam volume that was originally 99% of the foam volume that was originally present imme present immediately after creating the foam. diately after the foaming process. If, on the other hand, a 0018. In a modification of the above specified embodi liquid, foamable composition which has an especially large ment of the invented method, another embodiment calls for foam Volume is desired, then the nature and/or the concentra selecting a foam applicator for the mechanical foaming of the tion of the minimum ingredients of the liquid composition liquid composition, a foam is created from the liquid compo will be varied so that an especially high foam volume results sition by the selected foam applicator, and a correlation is in the SITA measurement method, i.e., a foam volume that produced between the properties, especially the pharmaceu varies between 600 ml and 1200 ml or even up to 1400 ml. tical properties of the foam created via the foam applicator 0012 For example, a method of the invention proposes a and the foam volume and/or the foam stability as determined standardized method in which, by variation of the chemical via the SITA measurement method. This embodiment of the nature of the ingredients and/or their concentration, one can invented method allows one to develop foams with defined develop a foam quantified in the above sense with regard to foam volumes and foam stabilities, as measured by the SITA the foam volume and the foam stability, and which can measurement method, especially easily and quickly by vary accordingly be applied to the skin of humans and animals. ing the nature and/or the concentration of the ingredients of 0013. It should be noted for clarification that the term skin the liquid pharmaceutical composition, which then correlate in the sense of the present specification covers not only the with the foams that are later applied as foam to the skin by the actual skin, but also the mucous membrane in mouth, nose, selected foam applicator. vagina or foreskin, the areas of the ear and especially the areas 0019 Especially when the development method of the of the inner ear, the area of the anus and the rectum, the area invention is used to create afoam from the liquid composition of the eyes, especially the area under the eyelid, Such as the that possesses a foam density between 0.05 g/ml and 0.8 g/ml, conjunctiva, cornea and lacrimal sac, the nails and scalp. preferably between 0.15 g/ml and 0.4 g/ml by the SITA mea these being the preferred sites of application of the foam Surement method, it has been found that such liquid compo US 2016/0022579 A1 Jan. 28, 2016

sitions provide excellent foams that can be applied with a 0025. Furthermore, preferred surfactant foaming agents number of differently designed, mechanical-type foam appli are chosen from the group consisting of alkylcarboxylates, CatOrS. alkylsulfates, alkylsulfonates, alkylethercarboxylates, Sul 0020. In an embodiment, the chemical nature and/or the fates of fatty acids, phosphates of fatty acids, Sulfonates of concentration of ingredients (solvent, foaming agent, active fatty acids, salts of sulfates offatty acids, salts of sulfonates of ingredient) are varied in the method of the invention so as to fatty acids, fatty acid amides, polyalkylenes, fluoroSurfac ensure the foam volume and the foam stability as indicated tants, soaps, metal soaps, especially alkaline soaps, such as above in the development method of the invention. In particu Sodium, potassium and ammonium salts of aliphatic carboxy lar, the solvent for the production of the liquid composition in lic acids, organic amino-Soaps, especially organic amine the method of the invention may be chosen from the group Soaps of aliphatic carboxylic acids, quaternary ammonium consisting of water, at least one alcohol, especially at least compounds, especially benzalkonium chloride, octadecy one monovalent to trivalent alcohol, at least one polyalcohol lammonium chloride, Sulfonium salts, amidoamines, fatty and mixtures of the aforementioned solvents. Of course, in acid esters, preferably monoglycerin, diglycerin and triglyc choosing the solvent one will make Sure that these solvents erin esters, fatty acid ethers, alkoxylated, especially ethoxy are skin-tolerated and especially do not result in any skin lated fatty acids, alkoxylated, especially ethoxylated fatty irritation, so that they are appropriately pharmaceutically acid derivates, alkoxylated, especially ethoxylated fatty alco applicable. Preferred solvents are 2-propanol, propylene gly hols, alkoxylated, especially ethoxylated phenols, alkoxy col, glycerin as well as polyols, while the term water com lated, especially ethoxylated fatty acid amides, mono- and prises all aqueous systems, especially also aqueous pharma dialkylalkanolamides or alkylpolyglucosides, especially ceutical buffer systems. coco-mono-ethanolamides, coco-di-ethanolamides, coco 0021. In an especially suitable embodiment of the method mono-isopropanolamides, coco-diglucosides, betaine, of the invention, the pharmaceutical active ingredient is used betaine derivates, preferably N-alkylbetaine, alkyl-ami as the foaming agent, so that this embodiment of the invented dopropylbetaine, Sulfobetaine, alkylsulfobetaine, alkylglyci method is based on the fact that it contains, besides the sol nate and alkylcarboxyglycinates, wherein the alkyl residue vent, only the pharmaceutical active ingredient whose con each time comprises in particular a carbon skeleton with 8 to centration and whose chemical nature are varied so that the 18 carbon atoms, acylamino acid, alkylimidazoline, N-Sub foam volumes and foam stabilities indicated in the method of stituted alkylamines, acyllactate, N-acylsarkosinate, alkano the invention and measured according to the SITA method are lamide, aminoxide, polyhydroxyalcohol esters, as well as guaranteed. mixtures and derivates of the aforementioned substances. 0022. Alternatively or in addition to this, a modification of 0026. As cationic surfactants that are likewise especially the method of the invention proposes that the foaming agent Suitable as the foaming agent in the method of the invention for the production of the liquid composition is chosen from for the production of the liquid composition, one will select the group comprising Surfactants, especially anionic, cat Substances which contain quaternary ammonium bonds, Sul ionic, nonionic and ampholytic Surfactants, silicones, fats, fonium salts, amidoamides and their mixtures as well as their fatty acids, fatty acid derivates, phospholipids, Sugar deri derivates. Vates, lipids, especially sphingolipids and glycolipids, and 0027 Preferred ampholytic surfactants for the production mixtures and derivates of the aforementioned substances. of the liquid composition will be chosen from the group 0023 Foaming agents, whether the active ingredient itself comprising betaine and betaine derivates. or the above listed foaming agents, may be capable of provide 0028. As for the active ingredients used in the method of the aforementioned foam Volumes and foam stabilities as the invention, these will preferably be active ingredients such Soon as the liquid composition is foamed in purely mechani as are described in further detail in connection with the topi cal fashion, without the use of a propellant. Preferred surfac cally applicable composition according to the invention. tants include the fatty alkyl ether sulfates, the alkyl phos 0029 Besides the repeatedly aforementioned solvent, the phates, the alkyl ether phosphates, the alkyl benzene pharmaceutical active ingredient and the foaming agent, in Sulfonates, the petroleum Sulfonates, the olefin Sulfonates further embodiments of the invented method for production and/or the esters of SulfoSuccinic acid. Among the silicones, of the liquid composition that is foamed in purely mechanical one should mention especially modified siloxanes, polydi fashion for its application, there is proposed in particular a alkyl siloxanes and preferably linear or cyclical polydimethyl complexing agent, a buffer, a thickening agent, an antioxidant siloxanes. Fats and modified fats, such as fatty acids, fatty and/or a stabilizer. However, one must make pay heed that acid derivates, fatty acid esters, as well as synthetic, plant and these aforementioned ingredients can also have an influence animal phospholipids, especially phosphatidylcholine and/or on the foam volume and the foam stability, but this can be hydrogenated phospholipids and preferably hydrogenated determined quite easily and without problem and within the phosphatidyl choline, are among the preferred foaming shortest time in a reproducible manner by the method of the agents, in addition to the sphingolipids, glycolipids and Sugar invention. derivates, preferably sugar or sorbitol esters. 0030. As already mentioned above, the present invention 0024. Among the fat derivatives, especially the sulfates of furthermore concerns atopically applicable composition with fatty acids, sulfonates of fatty acids, salts of sulfates of fatty the features of the preamble of patent claim 9. acids, salts of Sulfonates of fatty acids, soaps and mixtures 0031. The topically applicable composition of the inven and derivates of the aforementioned substances are especially tion, which is developed preferably but not exclusively Suitable as foaming agents for use in the method of the inven according to the above described method of the invention, tion. This holds likewise for alkoxylated fatty acids and has, a pharmaceutical active ingredient, a solvent as well as a alkoxylated fatty acid derivates, alkoxylated fatty alcohols, foaming agent. In contrast to the known liquid composition of alkoxylated phenols as well as mixtures and derivates of the EP 0510561 for example, which is applicable as a foam, the aforementioned substances. topically applicable composition of the invention proposes a US 2016/0022579 A1 Jan. 28, 2016 phospholipid foaming agent as the foaming agent. Further 0034. As already explained above for the method of the more, the at least one phospholipid foaming agent, the at least invention, the composition according to the invention may one solvent and the at least one active ingredient in the com include, as a solvent, especially water, at least one alcohol, position of the invention are attuned to each other in their especially at least one polyvalent to trivalent alcohol, and/or chemical nature and/or their concentration so that the com at least one polyalcohol, and Such solvents are chosen in position can be mechanically foamed exclusively without the particular for Such phospholipid foaming agents as contain a use of an additional propellant. The foam so created by the phospholipid and/or a phospholipid mixture isolated from mechanical foaming during the application has a foam Vol plant components, especially soybeans. ume of at least 400 ml, preferably between 450 and 1400 ml 0035. For clarity it is pointed out that the term phospho and especially a foam volume between 600 and 1200 ml. lipid mixture orphospholipids in the above description covers Furthermore, the composition according to the invention has all phospholipids of plant origin, animal origin, or synthetic such a foam stability that the foam still has, after a dwell time origin. In particular, this includes the ester phospholipids, of up to ten minutes and especially after a dwell time of up to especially phosphatidylcholine, lyso-phosphatidylcholine, five minutes, at least 50% of the foam volume and especially phosphatidyl ethanolamine, lyso-phosphatidyl ethanola between 55% and 100% of the foam volume and preferably mine, phosphatidyl serine, lyso-phosphatidyl serine, phos between 85% and 99% of the foam volume that was originally phatidyl inositol, lyso-phosphatidyl inositol, phosphatidyl present immediately after the creation of the foam, wherein glycerin, diphosphatidylglycerin and the phosphatidic acids, both the aforementioned foam volume and the aforemen the ether phospholipids, especially choline plasmalogen and tioned foam stability can be determined by the standardized ethanolaminoplasmalogen, as well as the sphingosine phos SITA foam measurement method. In other words, topically pholipids, especially ceramide phosphorylcholine and phy applicable composition of the invention is characterized not toglycolipid and derivates of the ester phospholipids, the only by the nature of its ingredients and/or their concentra ether phospholipids and/or the sphingosine phospholipids, tion, but also by the foam created from it, wherein the foam is regardless of whether they have been isolated from natural specified and quantified in terms of the foam Volume and the Substances, such as plants or plant components, especially foam stability by the standardized SITA measurement plant seeds, or animal components, such as eggs, or syntheti method. cally produced. Typical derivates of these phospholipids 0032. The composition of the invention has a number of which can be contained in the composition of the invention as advantages. When the composition of the invention is applied foaming agent are preferably the hydrogenated or partly to human or animal skin, where the term skin as already hydrogenated phospholipids, especially hydrogenated or defined above covers the mucous membranes of mouth, nose, partly hydrogenated phosphatidylcholine. vagina and foreskin, the skin areas of the ear and especially 0036 Regarding the active ingredient, it should be noted the inner ear, the skin areas of the anus and the rectum, the that the at least one active ingredient contained in the com nails and the eyes, especially the conjunctiva, the cornea and position of the invention is one that is suitable for use on the lacrimal sac, the foam created from the composition of the humans or animals and especially for topical and systemic invention has, first of all, an excellent adhesion to these appli application, especially on the skin, wherein an especially cation sites, so that it cannot easily be wiped off unintention preferred active ingredient is chosen from the group compris ally. Moreover, the foam produced in exclusive mechanical ing local anesthetics, anti-allergic agents, dermatics, active fashion from the liquid composition of the invention has a ingredients against flu infections and colds, active ingredients naturally homogeneous composition, and the pharmaceutical for the treatment of neuropathies, active ingredients for the active ingredient is present in this foam in an especially uni treatment of disturbed circulation, chemotherapy drugs, qui formultrafine distribution, so that once the foam breaks down nine, antimycotics, antibiotics, thalidomide, serotonin, after being applied this ultrafine distribution is retained in the eicosanoids, analgesics, anticonvulsants, nonsteroidal anti liquid layer formed on the skin surface, with the result that the rrheumatics, leukotrienes, leukotriene inhibitors, androgens, pharmaceutical active ingredient is transported with a high antiandrogens, corticoids, opiate receptor antagonists, blood rate of penetration and/or permeation into and/or through the clotting inhibitory Substances, thrombocyte aggregation skin. This, in turn, means that the active ingredient so applied inhibitors, histamine antagonists, regulatory and enzymati has a high pharmaceutical efficacy, so that if desired the cally acting peptides and proteins, nucleic acids (single and concentration of active ingredient in the composition of the double-stranded DNA, single and double-stranded RNA, invention can be reduced as compared to traditional compo snRNA, DNA oligonucleotides, RNA oligonucleotides) and sitions or, alternatively, the time intervals between consecu oligopeptides, antipruritics, antidiabetics, prostaglandins, tive applications can be lengthened appropriately, especially prostaglandin synthesis inhibitors, antiviral-acting or viro since the active ingredient forms a depot in the skin. Due to static-acting Substances, antimicrobial-acting Substances, the fact that a phospholipid foaming agent is present as the active ingredients against prions, immune Suppressants, hor foaming agent in the composition of the invention, this phos mones, active ingredients for treatment of warts or wounds, pholipid foaming agent has the effect of producing a faster especially chronic wounds, vitamins, plant extracts or penetration or permeation into or through the skin, which essences of plant extracts, psychoactive drugs, active ingre proves to be an additional advantage of the composition of the dients influencing sleep, analeptics, general anesthetics, invention. muscle relaxants, antiepileptics, antiparkinson agents, anti 0033 Especially when the foam created from the compo emetics, antiparasitics, ganglion-active substances, sympa sition of the invention by the SITA measurement method has thetic-active Substances, parasympathetic-active Substances, a foam density between 0.05 g/ml and 0.8 g/ml, preferably antibacterial-acting drugs, calcium antagonists, cardiovascu between 0.15 g/ml and 0.4 g/ml, such embodiments of the lar agents, antiasthmatics, antitussives, expectorants, hepat compositions according to the invention have the aforemen ics, diuretics, choleretics, disinfectants, trace elements, anti tioned advantageous properties to an enhanced degree. infectives, cytostatics, antimetabolites, hormone antagonists, US 2016/0022579 A1 Jan. 28, 2016

immune modulators, as well as derivates and salts of the (III) sodium-gluconae complex, epoetin alpha, epoetin beta, aforementioned active ingredients. epoetin Zeta, erythropoetin, folic acid and methoxy-polyeth 0037 Depending on the particular use of the invented ylglycol-epoetin beta; for the main group of antiandrogens: composition, disclosed compositions can include an active bicalutamide, chlormadione and cyproterone; for the main Substance or a special active Substance mixture, which is group of antiarrhythmics: ajmalin, amiodaron, quinidine, chosen from the following listed special active Substances, detajmium bitartrate, flecainide, lidocaine, mexiletin, orci presented under their particular main groups prenalin, prajamalium bitartrate, propafenon and Sotalol; for 0038 Preferably, for the main group of the 5C.-reductase the main group of antibiotics or anti-infectives: amikacin, inhibitors, alphatradiol and 17C-estradiol can be used; for the aminosidine, paromomycin, chloramphenicol, ciprofloxacin, main group of weight loss agents, appetite curbing or anti clindamycin, colistimethate-sodium, colistin, enfuvirtid, obesity agents: norephedrine, phenylpropanole amine, enoxacin, flucloxacillin, fosfomycin, fusafungin, levofloxa D-norpseudoephedrin, orlistate and Sibutramine; for the main cin, lineZolid, mefloquin, metronidazol, mezlocillin, moxi group of ACE-inhibitors: benazepril, cilaZapril, quinapril, floxacin, norfloxacin, ofloxacin, oxacillin, penicillin G, peni ramipril, spirapril and trandolapril; for the main group of cillin V, phenoxymethylpenicillin, phenoxymethylpenicillin acidosis therapeutic or antihypoxemic agents: calcium-sa benZathin, pipemidinic acid, piperacillin, piperacillin+ trium-hydrogen-citrate; for the main group of astringents: taZobactam, proguanil, propicillin, pyrimethamine, aluminium chloride, aluminum diacetate, aluminum formate, retapamulin, rifaximin, roXithromycin, Sulbactam, Sulbac bismuth chloride oxide, bismuth gallate, polycresulene, tan tam--ampicillin, Sulfadiazine, spiramycin, Sultamicillin, taZo nin and Zinc oxide; for the main group of acne agents: aze bactam-piperacillin, teicoplanin, tellithromycin, tigecyclin lainic acid and benzoyl peroxide; for the main group of aldos and Vancomycin; for the main group of antidementia agents terone antagonists: canrenionic acid, potassium canrenoate, (nootropics): galantamine, nicergolin, nimodipin, pyracetem, dolasetrone and eplerenone; for the main group of alcohol pyritinol and rivastigmin: for the main group of antidepres withdrawal agents: acamprosate and disulfiram; for the main sants: agomelatin, amitriptylin, amitriptylin oxide, bupro group of C.1-receptor blockers: alfuZosin, bunaZosin and pion, citapram, clomipramin, dulloxetin, escitalopram, fluox dihydroergotamine; for the main group of O2-receptor ago etin, fluvoxamin, maprotilin, mianserin, mirtazapin, nist: apraclonidine, brimonidine, doxoZosine and moxoni nortriptylin, opipramol, paroxetin, reboxetin, Sertralin, tra dine; for the main group of C- and B-sympathomimetics: nylcypromin, traZodon and trimipramin; for the main group adrenaline, dobutamine, dopexamine and epinephrine; for the of antidiabetics: acarbose, exenatid, glibenclamide, gliclacid, main group of aminoglycoside antibiotics: gentamycin, kana glimepirid, gliquidon, insulinaspart, insulinaspart biphasic, mycin, neomycin, netilmycin, Streptomycin and tobramycin; insulindetemir, insulinglargin, insulinglulisin, human insu for the main group of amino acids: alanine, aminoacetic acid, lin, human insulin-isophanbiphasic, insulin-isophan, insulin glycine, arginine, asparagine, asparaginic acid, cysteine, cys lispro, isophan-insulin, metformin, miglitol, nateglinid, tine, glycocoll, ornithine, proline and serine; for the main pioglitazon, repaglinid, rosiglitazon, Sitagliptin and Vilda group of amino acid substitution: alanylglutamine, arginine gliptin; for the main group of antidotes: bis-Sulfanyl propane glutamate, desmeninol, glycylglutamine and glycyltyrosine; Sulfonic acid, deferasiroX, deferoxamin, deferipron, dimer for the main group of analeptics or antihypoxemics: camphor capto-propane Sulfonic acid, dimethylaminophenol, diso and caffeine; for the main group of analgesics or antirheu dium folinate, iron hexacyanoferrate, eserin, flumazenil. matics: abatacept, acetylsalicylic acid, acetaminophen, fomepizol, naloxone, sodium folinate, sodium thiosulfate, ademetionin, anakinra, aurothiomalate Sodium, buprenor obidoxim chloride, pentetic acid, physostigmin, Silbinin and phin, diethylamine Salicylate, etanercept, etoricoxide, fenta tolonium chloride; for the main group of antiemetics or anti nyl, flufenamine acid, flupirtin, glucosamine, hydromor Vertigo agents: aprepitant, beta-histine, domperidon, fluna phone, 2-hydroxybenzoic acid, diethylazane salt, rizin, fosaprepitant, granisetron, ondansetron, palonosetron hydroxychloroquin, hydroxyethylsalicylate, leflunomide, and tropisetron; for the main group of antiepileptic agents: levomethadone, meptazinol, metamizol, methylsalicylate, carbamazepin, clonazepam, diphenylhydantoin, phenytoin, misoprostol, morphine, nalbuphin, sodium aurothiomalate, dipropylacetic acid, valproic acid, ethoSuximid, felbamat, nicoboxil, nonivamide, noramidopyrine, novaminsulfone, gabapentin, potassium bromide, lacosamid, lamotrigin, leve oxaceprol, oxycodone, paracetamol, penicillamine, pethi tiracetam, mesuXimid, oXcarbazepin, phenobarbital, primi dine, phenaZone, piritramide, propylnicotinate, propy don, propylvalerianic acid, rufinamide, Sultiam, tiagabin, phenaZone, Salazosulfapyridine, SulfaSalazine, tilidine, tra topiramate, valproic acid, vigabatrin and Zonisamide; for the madol and Ziconotide; for the main group of acidification main group of antiestrogens: clomife; for the main group of agents: malic acid; for the main group of antacids: almasilate, antihemorrhagics, antifibrinolytics and other hemostatic aluminum hydroxide, aluminum hydroxide-magnesium car agents: aminomethylbenzoic acid, human blood clotting fac bonate gel, aluminum phosphate, carbaldrate, magaldrate, tor 1, blood clotting factor V11a, blood clotting factor V11 magnesium carbonate, magnesium hydroxide and magne (CHO), recombinant blood clotting factor V111, human sium trisilicate; for the main group of antihelminthics: blood clotting factor V111, recombinant blood clotting factor albendaZol, mebendazol, niclosamide, praziquantel, pyrantel 1X, human blood clotting factor 1X, blood clotting factor and pyrviniumembonate; for the main group of antiallergics: X111, eptacogalpha (activated), fibrinogen, gelatins, moroc chromoglycinic acid, lodoxamide, meduitazine, mizolastine tocog alpha, nonacog alpha, octocog alpha (BHK), phytom and olopatadine; for the main group of antianemics: calcium enadione, human plasma proteins, human plasma proteins folinate, darbepoeton alpha, iron, iron carboxymaltose, iron with factor VIII inhibitor bypass activity, proconvertin, prota (II) chloride, iron (II) fumarate, iron (II) gluconate, iron (II) mine hydrochloride, tranexamic acid and troXerutin; for the Succinate, iron (II) sulfate, iron glycine Sulfate, iron (III) main group of antihistamines: anazolin, azelastin, bamipin, hydroxide-dextran complex, iron (III) hydroxide-polymal cetirizin, chlorphenamine, chlorphenoxamine, cyprohepta tose complex, iron (III) hydroxide-saccharose complex, iron dine, desloratadine, dexchlorpheniramine, dimenhydrinate, US 2016/0022579 A1 Jan. 28, 2016 dioxopromethazine, diphenhydramine, diphenylpyraline, atenolol, bisoprolol, betaxolol, bupranolol, carteolol, celip ebastine, emedastine, epinastine, feXofenadine, hydroxy Zine, rolol, esmolol, fosinopril, gallopamil, irbesartan, levocabastine, levocetirizine, loratadine, rupatadine, terfena levobunolol, lisinopril, losartan, metipranolol, metoprolol. dine, tripelennamine and triprolidine; for the main group of nebivolol, nifedipine, nisoldipin, oXprenolol, penbutolol, per antihypertonics: alliskiren, ambrisentan, amiloride+hydro indopril, pindolol, propranolol, talinolol, Valsartan and Vera chlorothiazide, hydrochlorothiazide--amiloride, bosentan, pamil, for the main group of bisphosphonates: alendronate, candesartan, captopril, clonidine, delapril, enalapril, enalap alendronatic acid, clodronate, clodronic acid, etidronate and rilate, eprosartan, hydralazine, imidapril, indapamide, etidronic acid; for the main group of broadband penicillin: indoramine, lercanidipine, manidipine, methyldopa, minoxi amoxicillin and amplicillin; for the main group of broadband dil, moexipril, nilvadipin, nitrendipin, nitroprusside Sodium, penicillin+B-lactamase inhibitors: clavulanic acid and Sul olmesartan, praZosin, reserpine, nitrogen monoxide, sitaxen bactam; for the main group of bronchodilators: aminophyllin tan, telmisartan, teraZosin, treprostinil and urapidil; for the and bambuterol; for the main group of broncholytics or anti main group of antihypoglycemics: diaZoxide and glucagon; asthmatics: carbocisteine, ciclesonide, clenbuterol, fenoterol, for the main group of antihypotonics: amezinium methyl formoterol, ipratropium bromide, ketotifen, montelukast, Sulfate, cafedrin, dopamine, etillefrin, levarterenol, norepi omalizumab, reproterol, Salbutamol, Salmeterol, terbutalin, nephrine, midodrin, noradrenaline, oxillofrin and theodrena theophyllin, theophyllin ethylene diamine, tiotropium bro line; for the main group of anticoagulants: bivalirudin, certo mide and tulobuterol; for the main group of calcium antago parin Sodium, dabigatran, dalteparin Sodium, danaparoid nists: amlodipin, diltiazem, felodipin and isradipin; for the Sodium, drotrecogin alpha (activated), enoxaparin Sodium, main group of calcium replacement agents: calcium amino fondaparinux, heparin, heparin (low-molecular), nadroparin ethyl phosphate, calcium aspartate, calcium bis-(hydrogen calcium, reviparin sodium, tinzaparin Sodium, lepirudin, aspartate), calcium chloride, calcium citrate, calcium glucon nadroparin calcium, pentosanpolysulfate Sodium, protein C, ate, calcium hydrogen phosphate, calcium hydrogen phos reviparin sodium, rivaroXaban, tinzaparin Sodium and war phate, calcium lactobionate, calcium lactogluconate and cal farin; for the main group of antimycotics: amorolfin, ampho cium salts; for the main group of carboanhydrase inhibitors: tericin B, anidulafungin, bifonazole, caspofungin, ciclopirox, acetazolamide, binzolamide and dorzolamide; for the main ciotrimazole, econazole, fenticonazole, fluconazole, flucy group of cephalosporin: cefaclor, cefadroxil, cefalexin, cefa tosin, griseofulvin, hexamidine, isoconazole, itraconazole, Zolin, cefepim, cefixim, cefotaxim, cefotiam, cefepodoxim, ketoconazole, micafungin, miconazole, naftifin, natamycin, ceftazidim, ceftibuten, ceftriaxon, cefuroxim and ceph; for nystatin, oxiconazole, posaconazole, sertaconazole, terbina the main group of chemotherapy agents: co-trimoxazole, dap fin, tioconazole, tolnafiat, undecylenic acid and Voriconazole; son, nifuratel, nitrofural, nitrofurantoin, nitrofurazon, for the main group of antineoplastic agents: alemtuzumab, nitroxolin, octenidin, pentamidin, ulfamethoxazole, tauroli alitretinoin, bevacizumab, arsenic trioxide, asparaginase, din and trimethoprim; for the main group of cholagogues and bexaroten, buserelin, celecoxib, cetuximab and colaspase; for bile duct therapeutic agents: menthon, C-pinene, B-pinene the main group of antiparasitic agents: allethrin 1, acetic acid, and ursodesoxycholic acid; for the main group of cholin permethrin and piperonylbutoxide; for the main group of ergics: acetylcholine chloride, carbachol, distigmin bromide, antiphlogistics: aescin, ammonium bituminosulfonate, neostigminand pyridostigmin bromide; for the main group of ammonium bituminosulfonate bright, benzydamine, bufex corticoids: fludrocortisone for the main group of depot peni amac, cumarin, dimethylsulfoxide, guaiaZulene, sodium cillin: benzylpenicillin-benzathin and benzylpenicillin bituminosulfonate and serrapeptase; for the main group of procaine; for the main group of dermatic agents: ammonium antipruriginosics: crotamiton, levomenthol, menthol and coal dodecylsulfate, betacarotene, DFMO, eflornithine, difluorm tar; for the main group of antipsoriatics: acitretin, dimethyl ethylornithine, dodecylbenzene sulfonic acid, nitrilotrietha fumarate and ethylhydrogenfumarate; for the main group of nol salt, ectoin, estradiol benzoate, ethyllinolate, framycetin, antipsychotics: aripiprazole; for the main group of antisep fusidinic acid, synthetic tannin, phenol-methanal-urea poly tics: ethacridin, ethanol, denatured ethanol, fenchon, glyoxal, condensate Sulfonated, urea, hexamethylene tetramine, hyd hexetidin, hydroxyquinoline Sulfate, potassium thiocyanate, roquinone, isotretinoin, potassium hydroxide, keratin, copper methenamine-silver nitrate 1:2, phenoxyethanol, ionic silver (II) nitrate, lithium Succinate, methane thelinium bromide, and colloidal silver; for the main group of antiscabies agents: methenamine, methoxypsoralene, mupirocin, nadifloxacin, benzylbenzoate; for the main group of antitussives or expec pimecrolimus, podophyllotoxin, Salicylic acid, nitric acid, torants: anethol, benproperin, cineol, codeine, dextrometho Selenium disulfide, Sulfadiazine-silver, tacalcitol, tretinoin rphan, dihydrocodeine, dropropizin, eucalyptol, guaifenesin, and tyrothricin; for the main group of disinfectants: amino guajacol glycerine ether, levodropropizin, narcotin, sodium propyldodecylpropane diamine, cocospropylene diamine, dibunate, noscapin, pentoxyverin, thymol and tyloxapol; for dodecylpropane diamine, ethylene dioxydimethanol and tri the main group of anticoagulants: argatroban; for the main closan; for the main group of disinfectants or antiseptics: group of anxiolytics: buspiron; for the main group of appetite aethacridin, aluminum acetate tartrate, amylmetacresol, curbing agents: amfepramon and cathine; for the main group bibrocathol, benzalkonium chloride, benzethonium chloride, of aromatase inhibitors: anastroZole, exemestan and letro benzyl alcohol, bishydroxymethyl urea, biphenyl-2-ol, bro Zole; for the main group of arteriosclerosis agents: dode mchlorophen, cetylpyridinium chloride, 8-quinolinol Sulfate, cyltetradecylhydroxypolyoxyethylene polyoxypropylene; clioquinol, didecyldimethylammonium chloride, didecylm for the main group of balneotherapeuticals and thermo ethyloxyethlammonium propionate, quinolinol Sulfate potas therapy agents: humic acids; for the main group of B-lactam sium Sulfate, chlorhexidin, chlorhydroxybenzoic acid, cloro antibiotics: aztreonam, imipenem, cilastatin, doripenem, fen, cocospropylene diamine guanidinium acetate, ertapenem, loracarbef, meropenem; for the main group of dequalinium chloride, dibromhydroxybenzene Sulfonic acid, beta-receptor and calcium channel blockers and inhibitors of dichlorbenzyl alcohol, dithranol, ethylhexanol, formalde the renin-angiotensin-aldosterone system: acebutolol. hyde, glucoprotamine, glutaral, magnesium monoperoxyph US 2016/0022579 A1 Jan. 28, 2016 thalate, mecetronium ethylsulfate, oligodiiminoimidocarbo gemeprost, copper, metergolin, methylergometrin, lactic nyliminohexamethylene, ortho-phthalaldehyde, peracetic acid, nonoxinol, progesterone, prostaglandin E2, quinagolide acid, polyhexanid, povidone iodine, 1-propanol, 2-propanol, and Sulprostone; for the main group of hemopoietic growth tetrahydrotetrakishydroxymethylimidazoimidazoldione, factors: becaplermin; for the main group of hemostyptics: tosylchloramide Sodium and hydrogen peroxide; for the main cellulose oxidized regenerated, desmoressin and collagen; group of deodorants: chlorophyllin; for the main group of for the main group of hepatics: acetylmethionine, betaine dietetics or nutritional Supplements: methyloxobutyric acid, dihydrogen citrate, choline hydrogen tartrate, potassium methyloxovalerianic acid (3), methyloxovalerianic acid (4) iron-phosphate-citrate complex, ornithine aspartate and Zinc and oxophenylpropionic acid; for the main group of diagnos acetate; for the main group of cardioglycosides (Digitalis tic agents and diagnosis preparation agents: aminolavulinic lanata): B-acetyldigoxin, digitoxin and digoxin; for the main acid, aminolevulinic acid, 5-amino-4OXopentanoic acid, group of hyperemization agents: benzylnicotinate and ceruletid, human corticorelin, iron oxide, ferumoxsil, fluo isobornylacetate; for the main group of hypnotics or seda rescein, gadobenic acid, gadobutrol, gadodiamide, gadofos tives: brotizolam, chloralhydrate, clomethiazole, doxy veset, gadopentetic acid, gadoteridol, gadoteric acid, gadox lamine, flunitrazepam, flurazepam, lormetazepam, melato etic acid, galactose, 13C-urea, hexylaminooXopentanoate, nin, midazolam, nitrazepam, temazepam, Zaleplon, Zolpidem indocyanine green, mangafodipir, palmitic acid, patent blue and Zopiclon; for the main group of pituitary and hypothala V, perflutren, polyvinyl chloride, protirelin, secretin, starch mus hormones, other regulatory peptides and their inhibitors: hydrolyzate, somatorelin, TRH and tuberculin purified for carbetocin, choriogonadotropin alpha, choriongonadotropin, human use; for the main group of direct parasympathomimet tetracosactid, B-1-24-corticotropin, follitropin alpha, fol ics: bethanechol chloride; for the main group of diuretics: litropin beta, ganirelix, gonadorelin, gonadotrophinum chori bumetanide, furosemide, piretanide, Spironolactone, onicum, gonadotrophinum hypophysicum, menotropin, lan torasemide, triamterene, triamterene--hydrochlorothiazide reotid, LH-RH. lutropin alpha, mecaserim, nafarelin, and Xipamide; for the main group of dopamine agonists: octreotid, oxytocin, Somatostatin, Somatropin, terlipressin, C-dihydroergocryptin; for the main group of circulation pro thyrotrophin, urofolitropin, urogonatropin and human moting agents: alprostadil, cinnarizin, moXaverin, naftidro growth hormone; for the main group of immunomodulators: furyl, pentoxifyllin, prostaglandin E1 and Xanthinol nicoti eculizumab, glatiramer, lenalidomide, lenograstim, palivi nate; for the main group of iron replacement: ammonium iron Zumab and pegvisomant; for the main group of immune Sulfate; for the main group of emetics: apomorphine; for the stimulants: aldesleukin, dimepranolacedoben, filgrastim, main group of withdrawal agents/agents for treatment of inosine, interferon alpha-2a, interferon alpha-2b, interferon addictive diseases: maltrexone, nicotine and Vareniclin; for the beta-1, interferon beta-1b, interferon gamma-1b, peg main group of enzyme replacement therapy for Fabry's Syn filgrastim, peginterferon alpha-2a and peginterferon alpha drome: agallsidase alpha and agallsidase beta; for the main 2b; for the main group of immune Suppressants: adalimumab, group of enzyme inhibitors, enzyme deficiency products and azathioprin, basiliximab, cyclosporin, cladribin, cyclosporin, transport proteines: carglumic acid, L-carnitine, levocar daclizumab, efalizumab, everolimus, immunglobulin Grab nitine, C1-esterase inhibitor, galsulfase, hyaluronidase, idur bit antihuman-T-cell, infliximab, muromonab-CD3, myco Sulfase, imiglucerase, laronidase and miglustat; for the main phenolate mofetil, mycophenolic acid, natalizumab, siroli group of enzyme replacement therapy in Pompe’s disease: mus, tacrolimus and tocilizumab; for the main group of alglucosidase alpha; for the main group of estrogens: estriol, infusion and standard injection solutions or organ perfusion conjugated estrogens and ethinylestradiol; for the main group Solutions: N-acetyltyrosine, gelatine poly Succinate, glucose, of fibrinolytics: alteplase, reteplase, Streptokinase, tenect glutamine, glycerol dihydrogen phosphate, human albumen, eplase and urokinase; for the main group of film forming potassium hydrogen glutamate, mannitol, Sodium aminoeth agents: carbomer and carmellose; for the main group of gall ylhydrogen phosphate, Sodium chloride, sodium hydrogen stone dissolvers: chenodesoxycholic acid; for the main group carbonate, oleic acid, 2-oxoglutaric acid, polyhydroxyethyl of gestagens: dienogest, drospirenone, dydrogesterone, starch, hydrochloric acid, taurine, trometamol and Xylitol; for gestodene, hydroxyprogesterone caproate, levonorgestrel, the main group of inhaled narcotics: desfluran, dinitrogen medrogestone, medroxyprogesterone, megestrolacetate, monoxide and isofluran; for the main group of intestinal norelgestromin, norethisterone, norgestimate and D-norg antiphlogistics: 5-aminosalicylic acid, mesalazin, (-)-C.-bis estrel; for the main group of glaucoma treatment: bimatoprost abolol, levomenol, bromelain and choline stearate; for the and latanoprost; for the main group of geriatrics: potassium main group of potassium replacement agents: potassium metabisulfite; for the main group of antipodagrics: acetate, potassium chloride, potassium hydrogen aspartate, probenecide; for the main group of glucocorticoids: alclom potassium hydrogen carbonate, potassium lactate and potas etaSone, amcinonide, beclometasone, betamethasone, budes sium malate; for the main group of potassium-sparing diuret onide, clobetasol, clobetaSone, clocortolone, cloprednol, ics: amiloride; for the main group of capillary sealing agents: deflazacort, desoximetasone, dexamethasone, diflorasone, calcium dobesylate; for the main group of cardiacs: enoxi diflucortolone, flumetasone, flunisolide, fluocinolonac mon, icatibant, B-methyldigoxin, methyldigoxin, milrinon etonide, fluocinonide, fluocortolone, fluorometholone, flu and oubain; for the main group of caries and parodontosis prednidene, fluticaSone, halometasone, hydrocortisone, agents and other dental preparations: dectaflur, sodium fluo hydrocortisone aceponate, hydrocortisone acetate, hydrocor ride and olaflur, for the main group of carminatives: dimeth tisone-17-butyrate, hydrocortisone hydrogen Succinate, ylpolysiloxane and dimethicone; for the main group of coro methylprednisolone, mometasonfuroate, prednicarbate, nary drugs: ivabradin and molsidomine; for the main group of prednisolone, prednisone, rimexolone, triamcinolone, triam laxatives: bisacodyl, glycerine, glycerol, lactulose, macrogol, cinolone acetonide, triamcinolone-16.21-diacetate and tri magnesium peroxide, Sodium dioctylsulfoSuccinate, sodium amcinolone hexacetonide; for the main group of gonadorelin laurylsulfoacetate, sodium monohydrogen phosphate, inhibitors: cetrorelix; for the main group of gynecologicals: Sodium picosulfate, sodium sulfate, syrupy paraffin, polyeth US 2016/0022579 A1 Jan. 28, 2016 ylene glycol and white Vaseline oil paraffin, for the main phosphate, lomefloxacin, methylhydroxypropylcellulose, group of photoprotective agents: actinoquinol; for the main naphazolin, nedrocromil, oxybuprocaine, pegaptainib, pilo group of lipid lowering drugs: atorvastatin, beZafibrate, col carpin, polymyxin B, poly(vinylalcohol), povidone, ranibi estyramine, cholestyramine, etofibrate, etofyllin clofibrate, Zumab, Scopolamine, Sulfacetamide, tafluprost, tetry Zolin, eZetimib, fenofibrate, fluvastatin, gemfibrozil, lovastatin, timolol, travoprost, tropicamide, Verteporfin and wool wax magnesium pyridoxal phosphate glutamate, nicotinic acid, alcohols; for the main group of osteoporosis/calcium/bone omega-3-acid ethyl ester, pravastatin and simvastatin; for the metabolism regulators: alphacalcidol, calcitonin, disodium main group of topical anesthetics or neural therapeuticals: fluorophosphate, eptotermin alpha, hydroxycolecalciferol, aethoform, p-aminobenzoic acid ethyl ester, articaine, ben ibandronate, ibandronic acid, pamidronate, pamidronic acid, Zocaine, bupivacaine, carticaine, chlorethane, cinchocaine, human parathyroid hormone, paricalcitol, raloxifen, distron ethyl choride, felypressin, macrogol lauryl ether, mepiv tium ranelate, risedronate, risedronic acid, teriparatid, tiludr acaine, prilocaine, procaine, proxymetacaine, quinisocaine, onate, tiludronic acid, Zoledronate and Zoledronic acid; for ropivacaine and tetracaine; for the main group of gastrointes the main group of otologic agents: docusate-sodium; for the tinal agents: hydrotalcit, lanSoprazole, loperamide, methyln main group of parkinson drugs and other agents against altrexone bromide, metoclopramide, Sodium alginate, extrapyramidal disturbances: benserazide, bromocriptine, olsalazin, omeprazole, oxetacaine, pancreas powder, pancre budipine, cabergoline, carbidopa, entacapone, levodopa, atin, pantoprazole, pepsin, pirenzepine, polymethylsiloxane, lisuride, metixene, pergolide, piribedil, pramipexol, procycli rabeprazole, racecadotril, ranitidine, silicon dioxide, simethi dine, rasagiline, ropinirole, rotigotine, selegiline, tetrabena cone. Sucralfate, Smectite, tannin-protein and tilactase; for the Zine, tiapride, tolcapone and trihexypenidyll; for the main main group of magnesium replacement agents: magnesium group of penicillins: benzylpenicillin and dicloxacillin; for chloride, magnesium salts and magnesium sulfate; for the the main group of phosphate binders: algeldrate, hydrated main group of macrollide antibiotics: azithromycin, bacitra aluminum oxide, calcium acetate and calcium carbonate; for cin, clarithromycin, daptomycin and erythromycin; for the the main group of phosphate replacement agents: sodium main group of migraine agents: almotriptan, eletriptan, glycerophosphate; for the main group of photosensitizers: ergotamine, froVatriptan, naratriptan, rizatriptan, Sumatriptan ammoidine and methoXSalene; for the main group of polyaro and Zolmitriptan; for the main group of mineral preparations: matic retinoids: adapalene; for the main group of proge calcium lactate, calcium saccharate, iron hydrogenaspartate, stagenics: desogestrel and etonogestrel; for the main group of potassium aminoethylphosphate, potassium citrate, magne protease inhibitors: atazanavir and lopinavir, for the main sium aminoethylphosphate, magnesium aspartate, magne group of proteinase inhibitors: antithrombin 111; for the main sium bis(hydrogenaspartate), magnesium citrate, magnesium group of protozoan agents: artemether and lumefantrine; for gluconate, magnesium hydrogen citrate, magnesium hydro the main group of psychoanaleptics: atomoxetin, metam gen glutamate, magnesium hydrogen phosphate, magnesium fepramon and methylphenidate; for the main group of psych orotate and magnesium oxide; for the main group of oenergetics: deanol; for the main group of psychopharmaceu homocysteinuria treatment agents: betaine; for the main ticals: doxepin, haloperidol, imipramine, lithium salts, group of Scleroderma and induratio penis plastica treatment lorazepam, medazepam, memantin, moclobemide, modafi agents: 4-aminobenzoic acid; for the main group of mucolyt nil, olanzapine, oxazepam, paliperidone, perazine, perphena ics: acetylcysteine; for the main group of mucolytics: desOX Zine, phenothiazines, pimozide, pipamperone, prazepam, yribonuclease and dornase alpha; for the main group of promethazine, prothipendyl, quetiapine, risperidone, Sertin muscle relaxants and reversers: alcuronium chloride, atracu dole, Sulpirid, thioridazine, thiocanthene, Venlafaxine, rium besylate, quinine, cisatracurium besylate, dantrolen, Ziprasidone, Zotepine and Zuclopenthixol; for the main group mivacurium chloride, orphenadrin, pancuronium bromide, of rhinologics or sinusitis agents: Emser salt, synthetic Emser pridinol, rocuronium bromide, Succinyl choline chloride, salt, natural sea salt, oxymetazolin, silver-protein acetyl tan suxamethonium chloride, Sugammadex, tetrazepam, tizani nate, tramaZoline, Xanthan gum and Xylometazoline; for the din, tolperison and Vecuronium bromide; for the main group main group of roborants or tonics: iron (III) citrate and of myotonolytics: baclofen and methocarbamol; for the main glutaminic acid; for the main group of X-ray contrast agents: group of narcosis agents: esketamine, etomidate, hydroxybu amidotrizoic acid, barium sulfate, diatrizoate, iobitridol, tyiric acid, ketamine, propofol, remifentanil, sevofluran, iodixanol, iohexol, iomeprol, iopamidol, iopromide iosarcol, Sufentanil and thiopental-sodium; for the main group of neu iotrolan, iotroXic acid, ioxaglic acid and ioxitalamic acid; for roleptics: amisulpride, aaphenothiazine, pothipendyl, bmperi the main group of Saluretics: bemetizide, bendroflumethiaz dol, bomperidol, butyrophenone, chlorprothixen, clozapine, ide, chlorthalidone, clopamide, hydrochlorothiazide, hydro diphenylbutylpiperidine, droperidol, fluspirilen, pimozide, chlorothiazide--amiloride, hydrochlorothiazide--triamterene flupentiXol, fluphenazine, levomepromazine and melperone; and mefruside; for the main group of thyroid therapeutic for the main group of neuropathy drugs and other neurotropic agents: cinacalcet, potassium iodide, levothyroxin, liothyro agents: cytidine phosphate, A-liponic acid, thioctic acid, pre nin, Sodium iodide, sodium perchlorate, propylthiouracil, gabalin, riluzol and uridine phosphate; for the main group of thiouracils and L-thyroxin; for the main group of essential nonsteroidal anti-inflammatory drugs: flurbiprofen, ketoro amino acids: histidine, isoleucine, leucine, lysine, phenylala lac-tromethanol, lomoxicam and parecoxib; for the main nine, threonine, tryptophan, tyrosine and valine; for the main group of nonsteroidal antirheumatics: acecolfenac, aemeta group of secretolytics: ambroxol and bromhexine; for the cin, alizapride, chloroquin, dexibuprofen, diclofenac, etofe main group of serums, immunglobulins and inoculants: namate, ibuprofen, indomethacin, ketoprofen, meloxicam, immunglobulin (anti-D), immunglobulin (botulismus), nabumeton, naproxen, phenylbutaZone, piroxicam, proglu immunglobulin (cytomegalia), immunglobulin (hepatitis B), methacin and tiaprofenic acid; for the main group of oph immunglobulin (human), immunglobulin (tetanus), immun thalmics: chondroitin Sulfate, gramicidine, hydroxypropyl globulin (rabies) and immunglobulin (varicella-Zoster); for guar, hydroxypropylmethylcellulose, hypromellose, inosine the main group of sexual hormones and their inhibitors: estra US 2016/0022579 A1 Jan. 28, 2016

diol, estradiol Valerate, mestranol, mifepristone, prasterone, enate, nicotinamide, nicotinic acid amide, pyridoxin, retinol, testosterone and tibolone; for the main group of spasmolytics riboflavin, thiamine, thiamine dihydrogen phosphate-dihy oranticholinergics: atropine, atropine Sulfate, biperiden, bor drogen phosphate (ester salt), thiamine disulfide, thiamine naprine, borneol, butylscopolaminium bromide, camphen, nitrate, C-tocopherol, RRR-O-tocopherol, C.-tocopherol cyclopentolate, darfenacin, glycopyrronium bromide, hyme acetate, RRR-C-tocopherol acetate, DL-C.-tocopherol hydro cromone, hyoscine butylbromide, mebeverine and pipen gen Succinate, RRR-C-tocopherol hydrogen Succinate, Vita Zolate bromide; for the main group of trace elements: bis(L- min A, vitamin-A-acid, vitamin B, Vitamin B vitamin B. histidinato)Zinc, chromium chloride, chromium hydrogen Vitamin B, Vitamin C. vitamin D. Vitamin D. Vitamin E and vitamin K; for the main group of wound and scar treat aspartate, cobalt hydrogen aspartate, iron (III) chloride, cop ment agents: allantoin, calcium alginate, dexpanthenol, eth per (II) chloride, copper (II) hydrogen aspartate, manganese ylcyanoacrylate, lactide-caprolactone copolymers, poly(bu (II) chloride, manganese (II) hydrogen aspartate, sodium tylmethacrylate-co-methylmethacrylate) (x:y), polyurethane molybdate, sodium selenite, Zinc aspartate, Zinc bishydrogen and titanium dioxide; for the main group of urine acidification aspartate, Zinc chloride, Zinc gluconate, Zinc histidine, Zinc agents: ammonium chloride; for the main group of cytore orotate and Zinc sulfate; for the main group of replacement ductive agents: anagrelid; for the main group of cytostatics, agents: disodium hydrogen citrate, magnesium acetate, other antineoplastic agents and protectives: adriamycin, ame Sodium acetate, sodium hydroxide and sodium lactate; for the thopterin, bendamustine, bleomycin, bortezomb, buSulfan, main group of sympathomimetics: diplivefrin and ephedrine; capecitabine, carboplatin, CCNU, lomustine, chlorambucil, for the main group of tetracyclines: chlortetracycline, deme cisplatin, cyclophosphamide, cytarabine, dacarbazine, dasa clocycline, doxycycline, meclocycline, minocycline, oxytet tinib, daunorubicin, dexraZOXan, docetaxel, doxorubicin, epi racycline and tetracycline; for the main group of platelet rubicin, erlotinib, estramustine, etoposide, fludarabine, fluo clotting inhibitors: abciximab, cilostazol, clopidogrel, eptifi rouracil, flutamide, 5-FU, fulvestrant, gemcitabine, batide, iloprost, ticlopidine and tirofiban; for the main group goserelin, hydroxycarbamide, ibritumomabtiuXetan, idarubi of thyreostatics: carbimazole, methimazole and thiamazole; cin, ifosfamide, imatinib, irinotecan, lapatinib, leuprorelin, for the main group of tocolytics: atosiban; for the main group melphalan, mercaptopurine, mesna, methotrexate, methy of toxoplasmosis, pneumocystis carinii and pneumonia laminooxopentanoate, miltefosine, mitomycin, mitotane, drugs: atovaquone; for the main group of tranquilizers (ben mitoxantrone, nelarabine, nilotinib, nimustin, oxaliplatin, Zodiazepin): alprazolam, bromazepam, chlordiazepoxide, paclitaxel, palifermin, panitumumab, pegaspargase, pemetr clobazam, diazepam and dipotassium clorazepate; for the exed, porfimer-sodium, procarbazine, rasburicase, rituximab, main group of tuberculosis drugs: aminosalicylic acid, Sorafenib, Sunitinib, tamoxifen, tegafur, temoporfin, temoZo ethambutol, isoniazide, protionamide, pyrazinamide, lomide, temsirolimus, thiotepa, thioguanine, topotecan, rifampicin and terizidone; for the main group of ulcer thera toremifene, trabectedline, trastuzumab, treosulfan, triptorelin, peuticals: bismuth nitrate, bismuth tetraoxodialuminate, trofosfamide, uracil, vinblastin, Vincristin, Vindesine and cimetidine, esomeprazole and famotidine; for the main group vinorelbine; for the main group of biomaterials or medical ofuricostatics: allopurinol and benzbromarone; for the main plastics or various materials: hydroxylapatite, methyl group of urologicals: dutasteride, fesoterodine, finasteride, methacrylate, poly(methylacrylate-co-methylmethacrylate) flavoxate, potassium aminobenzoate, potassium sodium hydrogen citrate, lanthanum (III) carbonate, mercaptamine, (x:y), tricalcium bisphosphate and Zirconium (IV) oxide as methionine, oxybutynine, phenoxybenzamine, phytosterol, special active Substance or active Substance mixture. polystyrene divinylbenzene Sulfonic acid, polystyrene Sul 0039. An especially suitable embodiment of the composi fonic acid, propiverine, propyl-4-hydroxybenzoate, seve tion according to the invention proposes that this embodiment lamer, Solifenacin, tamsulosin, tiopronin, tolterodine, tro of the invented composition has, as active ingredient, an anal spium chloride and yohimbin; for the main group of uterus gesic, especially an analgesic that is chosen from the above agents: dinoprostone; for the main group of vasodilators: indicated special analgesics, and the content of this analgesic adenosine, buflomedil, carvedilol, codergocrin, dihydrala in the liquid composition that is mechanically foamed is Zine, dihydroergotoxin, dipyridamol, glycerol trinitrate, isos varied in particular between 0.1 wt.% and 20 wt.%, prefer orbide dinitrate, isosorbide mononitrate, nitroglycerin, pen ably in a concentration between 2 wt.% and 10 wt.%. taerythrity1 tetranitrate, sildenafil, tadalafil, trapidil and 0040. If the composition of the invention is to be used as Vardenafil; for the main group of venous therapeuticals: hep foam for treatment of fungal infections, then it may include, arinoids, mucopolysaccharide polysulfuric acid esters, oligo as pharmaceutical active ingredient, at least one antimycotic, (O-sulfo)rutoside, polidocanole, rutin and rutoside; for the especially an antimycotic that is chosen from the above indi main group of vein tonic agents: dioSmin; for the main group cated special antimycotics. Preferably this antimycotic is of virustatics: abacavir, aciclovir, adefovir, amantadine, chosen from the group comprising chlotrimaZol, biphonazol. brivudin, cidofovir, darunavir, didanosine, efavirenz, emitric econazol, phenticonazol, isoconazol, oxyconazol, Sertacona itabine, entecavir, etravirine, famciclovir, fosamprenavir, Zol, thioconazol, terbinafin, myconazol, ketoconazol, itra ganciclovir, idoxuridine, imiquimod, indinavir, interferon conazol, fluconazol, Voriconazol, as well as derivates of the beta, lamivudine, maraviroc, nelfinavir, nevirapine, Oselta aforementioned substances. mivir, raltegravir, ribavirin, ritonavir, saquinavir, stavudine, 0041. In particular, the concentration of an antimycotic telbivudine, tenofovir, tipranavir, trifluridine, tromantadine, active substance varies between 0.01 wt.% and 10 wt.%, Valaciclovir, Valganciclovir, Zanamivir and Zidovudine; for especially between 0.2 wt.% and 5 wt.%, in terms of the the main group of vitamins: aneurin, ascorbic acid, benfo liquid composition that is exclusively mechanically foamed tiamine, biotin, calcifediol, ergocalciferol, calciferol, calci during application. A foam produced in exclusively mechani potriol, calcitriol, calcium pantothenate, collecalciferol, cal fashion from Such a liquid composition during its appli cyanocobalamine, dihydrotachysterol, hydroxocobalamine, cation can then be used in particular with a very high phar purified silicon dioxide, sodium ascorbate, Sodium pantoth maceutical efficacy for nail and foot fungal infections and for US 2016/0022579 A1 Jan. 28, 2016 saccharomycete infections, the high pharmaceutical efficacy 0048 Depending on the particular application of the being manifested in that these fungal infections are curtailed above-described embodiments of the composition of the already after a few applications and also healed in a short time invention, the concentration of the analgesic/antiphlogistic after the application is repeated. active Substance in the liquid composition will vary between 0042 Another embodiment of the composition according 0.5 wt.% and 8 wt.%, especially between 1 wt.% and 5 wt. to the invention includes as an active ingredient, at least one %. corticoid active ingredient, especially a corticoidactive ingre 0049. Of course, it is also possible for the composition of dient that is chosen from the above indicated special corticoid the invention to include, as active ingredient, a mixture of active ingredients, wherein the corticoid active ingredient is active ingredients, as long as this mixture of ingredients is chosen from the group consisting of glucocorticoids, mineral mutually compatible. Such embodiments of the composition corticoids and derivates of these. Depending on the particular of the invention will be used for treating generally milder skin corticoid active ingredient contained in the composition of ailments, such as milder forms of eczema, acne, lichen, insect the invention, the concentration of this corticoid active ingre bites, mycoses and/or treatments of Surface wounds with the dient varies between 0.001 wt.% and 3 wt.%, preferably foam created from the composition of the invention, in which between 0.1 wt.% and 0.8 wt.%. case the active ingredient or mixture of active ingredients is 0043 Preferred glucocorticoids are chosen from the group chosen from the group containing terbinafin, clobethasone consisting of clobetasol-17-propionate, diflucortolone-21 butyrate, erythromycin, benzocaine, dexamethasone, calci Valerate, amcinonide, betamethasone-17,21-dipropionate, potriol, tretinoin, minoxidil, bifonazole, dexpanthenol, Sali betamethasone-17-Valerate, desocimethasone, diflucor cylic acid, prednicarbate, momethasone furoate. tolone-21-Valerate, fluocinolone acetonide, fluocinonide, 0050. It should be clarified that all concentration figures fluocortolone, fluprednidene-21-acetate, fluthicasone-17 indicated in this specification refer each time to the liquid propionate, halcinonide, hydrocortisone-21-acetate-17-pro composition prior to its foaming, unless otherwise expressly pionate, hydrocortisone-17-butyrate-21-propionate, hydro cortisone-17-butyrate, methylpredisolonaceponate, indicated. momethasone, momethasone furoate, prednicarbate, triamci 0051. An especially suitable embodiment of the composi nolonacetonide, clobethasone butyrate, clocortolone-21-piv tion of the invention includes, as the phospholipid foaming alate, fluocortinbutyl, flumethasone-21-pivalate, hydrocorti agent, a phosphatidylcholine isolated from Soybeans, and in particular the concentration of this phosphatidylcholine in Sone and derivates of the aforementioned Substances. the phospholipid foaming agent is more than 50 wt.%, pref 0044 Another embodiment of the composition according erably between 50 wt.% and 95 wt.%, in relation to the dry to the invention proposes that the composition of the inven Substance of the phospholipid foaming agent. Especially tion contain, as active ingredient, at least one topical anes when this phospholipid foaming agent contains at most 15 wt. thetic, especially a topical anesthetic that is chosen from the % of lyso-phosphatidylcholine, at most 10 wt.% of phos above indicated special topical anesthetics, and the concen phatidic acid and at most 10 wt.% of phosphatidyl ethanola tration of this topical anesthetic, depending on the particular mine, one can create a foam with this special foaming agent active ingredient, varies in particular between 3 wt.% and 15 that can be diversely adapted to the particular requirements of wt.%, especially between 6 wt.% and 12 wt.%, in terms of the concentration of active ingredient in the liquid composi the application site by varying its concentration. tion. 0.052 Furthermore, in some embodiments, it may be 0045 Especially preferred topical anesthetics are chosen important for the aforementioned special foaming agent that from the group consisting of benzocaine, procaine, tetra the phosphatidylcholine contained in the phospholipid foam caine, lidocaine, etidocaine, prilocaine, mepivacaine, bupiv ing agent have an acid number of at most 10, a peroxide acaine. S-ropivacaine, articaine and their derivates. number of at most 10, and an oil concentration of atmost 6 wt. 0046. Another embodiment of the composition according % in terms of the dry substance of this phospholipid foaming to the invention calls for the composition to contain at least agent, the liquid composition forming the basis of the foam one immunomodulator in a concentration between 0.03 wt.% has an especially long shelf life, without requiring a higher and 0.1 wt.%, and the above indicated special immunomodu concentration of antioxidants or stabilizers, especially for the lators are especially preferred. aforementioned phospholipid foaming agent. 0047. An especially suitable modification of the compo 0053. The concentration of the phospholipid foaming sition of the invention comprises, as an active ingredient or agent contained in the liquid composition, in some embodi mixture of active ingredients, a nonopioid analgesic/antiphlo ments, should be such that the foams mentioned at the outset gistic agent, especially a non-opioid analgesic/antiphlogistic for the method of the invention and for the composition of the that is chosen from the above indicated special non-opioid invention and specified by the foam volume and by the foam analgesics/antiphlogictics. These include in particular the stability can be created. Preferably, aliquid composition salicylates, preferably acetylsalicylic acid and/or diflunisal, which is purely mechanically foamed has the phospholipid acetic acid derivates such as indomethacin, acemethacin, foaming agent in a concentration between 2 wt.% and 25 wt. diclofenac and/or lonazolac, propionic acid derivates Such as %, especially in a concentration between 4 wt.% and 15 wt. ibuprofen, flurbiprofen, ketoprofen, dexketoprofen, dexibu %. profen, tarenflurbil, nimeSulide, naproxen and/or thiaprofen 0054 The general remarks given above on the method of acid, oxicams, such as pyroxicam, tenoxicam, meloxicam the invention also hold for the composition of the invention, and/or lornoxicam, anthranylic acid derivates Such as mefe wherein the composition of the invention contains, besides naminic acid and/or flufenaminic acid, aniline derivates Such water, preferably an alcohol and especially propylene glycol, as paracetamol, and 1-phenyl-2,3-dimethyl-3-pyrazolin-5- whose concentration, depending on the desired and above one derivates, such as phenaZone, propyphenaZone and/or specified foam, varies between 2 wt.% and 25 wt.%, espe metamizol, their salts and their derivates. cially between 5 wt.% and 15 wt.%. US 2016/0022579 A1 Jan. 28, 2016

0055 As regards the pH value, it is stipulated that espe anaerobic microbes and mycoplasma, especially for treat cially the liquid composition of the invention has a pH value ment of acne, in a patient in need thereof, and comprises the that is skin-tolerated and, depending on the particular site of application of a foam containing an antibiotic, as is produced application, lies between 4.8 and 8.8. In order to assure the in particular from the previously described composition of the above-indicated pH value, it is especially advantageous to invention, to the skin of a warm-blooded mammal. Preferably add to the composition of the invention at least one buffer, in this treatment method the antibiotic chosen is erythromy especially sodium dihydrogen phosphate dihydrate and/or cin, especially in a concentration between 2 wt.% and 4 wt. disodium hydrogen phosphate dodecahydrate. %. 0056. The composition of the invention as described in 0063. In one embodiment, a method is contemplated for detail above can be foamed with any suitable foam applicator, the treatment of itching of the skin comprises the application e.g., the applicators made by Rexam/Airspray (rexamairspray of a foam containing a topical anesthetic, as is produced in dot corn, and made and marketed under the name M3 mini particular from the previously described composition of the foamer or those of made by Calmar/MeadWestvaco (Keltec), invention, to the skin of a warm-blooded mammal. Preferably and also disclosed in EP 0565 713 and EP 0 613728, hereby in this treatment method the topical anesthetic chosen is ben incorporated by reference, and where further technical details Zocaine and/or lidocaine, especially in a concentration about these foam applicators will be found. Thus, in particu between 1 wt.% and 20 wt.%, preferably 2 wt.% and 10 wt. lar, the present invention contemplates a foam applicator that %. includes a composition of the invention as described in detail 0064. In one embodiment, a method is contemplated for above. the treatment of psoriasis and comprises the application of a 0057 Moreover, the present invention relates to methods foam containing calcipotriol, as is produced in particular for treatment of the following illnesses. from the previously described composition of the invention, 0058. In one embodiment, a method is contemplated that to the skin of a warm-blooded mammal in need thereof. includes the treatment of atopic eczema or neurodermitis, Preferably the calcipotriol in this treatment method is pro wherein the treatment method of the invention involves the vided in a concentration between 0.005 wt.% and 0.05 wt.%. applying of a foam containing an immunomodulator, as is 0065. In one embodiment, a method is contemplated for produced in particular from the previously described compo the treatment of acne, especially acne comedonica and acne sition of the invention, to the skin of a warm-blooded mam papulopustulosa, comprises the application of a foam con mal in need thereof. In particular, tacrolimus is chosen as the taining tretinoin, as is produced in particular from the previ immunomodulator. Depending on the particular immuno ously described composition of the invention, to the skin of a modulator chosen, its concentration will vary preferably warm-blooded mammal in need thereof. Preferably in this between 0.03 wt.% and 0.1 wt.%. treatment method the tretinoin is provided in a concentration 0059. In one embodiment, a method is contemplated for between 0.05 wt.% and 0.1 wt.%. the treatment of inflammatory or pruritic skin ailments, pso 0066. In one embodiment, a method is contemplated for riasis, dermatitis, neurodermitis or psoriasis in a patient in treatment of hair loss comprises the application of a foam need thereof, comprising the application of a foam containing containing minoxidil, as is produced in particular from the a glucocorticoid, as is produced e.g. in particular from previously described composition of the invention, to the skin described compositions, to the skin of a warm-blooded mam of a warm-blooded mammal in need thereof. Preferably in mal. In particular, the glucocorticoid in this treatment method this treatment method the minoxidil is provided in a concen is chosen from the group consisting of betamethasone, dex tration between 38 wt.% and 6 wt.%. amethasone, predincarbate, mometasone furoate and clobe 0067. In one embodiment, a method is contemplated for tasone butyrate. Depending on the glucocorticoid, its concen the antiseptic treatment of treatment of Superficial wounds tration varies between 0.01 wt.% and 0.4 wt.%. comprises the application of a disclosed foam that may 0060. In one embodiment, a method is contemplated for include an antimycotic to a patient in need thereof. Preferably the treatment of of pain, inflammation, rheumatic ailments or in this treatment method the antimycotic is chosen from the acute trauma in a patient in need thereof and comprises the group comprising Preferably in this treatment method the application of a foam containing an analgesic, as is produced antimycotic is chosen from the group comprising, as is pro in particular from the previously described composition of the duced in particular from the previously described composi invention, to the skin of a warm-blooded mammal. Prefer tion of the invention, to the wound of a warm-blooded mam ably, the analgesic in this treatment method is chosen from the mal. Preferably in this treatment method the dexpanthenol is group consisting of diclofenac, ketoprofen and ibuprofen. provided in a concentration between 0.03 wt.% and 1 wt.%. Depending on the analgesic, its concentration varies between 0068. In one embodiment, a method is contemplated for 0.5 wt.% and 10 wt.%. the treatment of herpes and the side effects accompanying 0061. In one embodiment, a method is contemplated for herpes in a patient need thereof and comprises the application the treatment of of mycotic infections comprises the applica of a foam containing aciclovir, as is produced in particular tion of a foam containing an antimycotic, as is produced in from the previously described composition of the invention, particular from the previously described composition of the to the skin of a warm-blooded mammal. Preferably in this invention, to the skin or nails of a warm-blooded mammal in treatment method the aciclovir is provided in a concentration need thereof. Preferably in this treatment method the antimy between 3 wt.% and 7 wt.%. cotic is chosen from the group comprising bifonazole and 0069. In one embodiment, a method is contemplated for terbinafin. Depending on the antimycotic, its concentration the treatment of mild to medium severe psoriasis of the scalp varies between 0.1 wt.% and 20 wt.%, preferably between 2 in a patient in need thereof and comprises the application of a wt.% and 10 wt.%. foam containing salicylic acid, as is produced in particular 0062. In one embodiment, a method is contemplated for from the previously described composition of the invention, the treatment of infections with Gram positive microbes, to the scalp of a warm-blooded mammal. Preferably in this US 2016/0022579 A1 Jan. 28, 2016

treatment method the Salicylic acid is provided in a concen Surface, the foam Volume was measured immediately after tration between 8 wt.% and 12 wt.%. the five rotorcycles were completed. The foam stability was 0070. In the above description of the different embodi automatically detected by the instrument over a period of 35 ments of the method of treatment of the invention the term minutes in total for which the foam volume was measured application is used in the singular. However, this should also every 50 seconds by means of the needle detectors. The refer to the repeated application, at intervals of time, within a volume values so obtained were recorded directly by dedi given period, especially within 24 hours. cated software and hardware of the instrument. 0071. Likewise, the term skin used throughout the text 0078. The control system of the SITA foam tester is such covers not only the particular ailing regions of the skin, but that, after the measurement space is filled with 250 ml of also all surfaces of the human oranimal body accessible to the sample, the needle detectors travel only as far as the surface of application of the foam produced from the composition of the the sample and, accordingly, place the Zero point for the foam invention, and thus in particular, besides the skin or scalp Volume on the Surface of the measurement sample and not on itself, also nails, hair, teeth, hooves or the mucosa in mouth, the floor of the measurement space. After elapsing of the nose, vagina or foreskin, the regions of the ear and especially aforementioned rotor cycles for foaming the particular the inner ear, the region of the anus and the colon, the region sample, there sometimes remained in the measurement space of the eyes, especially the region under the eyelid, such as a liquid phase of the sample, depending on the composition of conjunctiva, cornea and lacrial sac, while the term mammal the particular sample being investigated, so that the Volume of comprises animals and humans. this liquid phase was also detected in the above described 0072 For clarity, and to avoid repetition, it is pointed out measurement according to the particular measurement value that the remarks, details and benefits described at the outset in of the foam Volume and is defined accordingly as foam Vol connection with the method of the invention also apply ume in the sense of the present specification, while the time accordingly for the composition of the invention and also the change in this foam Volume is the foam stability. In other above described treatment procedure of the invention, as do words, this means that, depending on the particular sample the remarks, details and benefits described in connection with measured, the foam Volume consists not only of the Volume of the composition of the invention for the method of the inven the actual foam, but also of the volume of nonfoamed liquid tion and the treatment procedure of the invention. sample remaining in the measurement space. 0073. The present invention shall be further described (0079. The following charts 1 to 17 plot all three measure hereafter by means of the following Examples. ment values for the particular composition, so that the repro ducibility of the measurement method can be seen quite well EXAMPLES from this. 0080 All the following sample embodiments in which Description of the SITA Measurement Method diclofenac is indicated as the active Substance have this active 0.074 For the determination of the foam volume and the Substance in the form of the Sodium salt of diclofenac, i.e., foam stability, a "SITA foam tester R-2000' (manufactured diclofenac-sodium. by SITA Messtechnik GmbH, Dresden) was used, as is Examples 1 to 5 described in detail in EP 1092970. This measurement device was provided with a rotor as shown in FIGS. 2 and 3 of DE I0081 Following the customary procedure, a composition 19740 0095 and also described there. This rotor consists of a containing ketoprofen, one containing lidocaine hydrochlo stirring shaft and a circular disk oriented perpendicular to ride, one containing prednicarbate, one containing diclofenac this, with a diameter of 70 mm, above and below the circular and one containing clotrimaZol were prepared, having the disk there being provided four symmetrical stirring blades, following ingredients: oriented at right angles to each other. Each stirring blade has a rectangular base Surface of 23 mmx12 mm. In cross section, Composition each stirring blade has the shape of a triangle, with a height of Ingredient in wt.% 5 mm, so that each stirring Surface accordingly forms a roof 1 Ketoprofen 10.00 with a ridge angle of 90 degrees. The stirring blades each 2 Propylene glycol 10.00 consist of a Conidur fine perforated plate (manufactured by 3 2-Propanol 8.00 Heinehmann, Krefeld) and have a plate thickness of 0.5 mm. 4 Phospholipid foaming agent A 10.00 a perforation of 0.5 and a spacing of 3.2. 5 Sodium hydrogen phosphate dihydrate O.25 6 Disodium hydrogen phosphate dodecahydrate, cryst. 0.57 0075. In all measurements, the sample volume was 250 7 Sodium hydroxide 1.55 ml, being automatically withdrawn by the measuring device 8 Peppermint oil O.15 from the reservoir tank, filled with at least 300 ml of sample. 9 Ultrapure water 59.48 The sample was placed carefully into the reservoir tank, avoiding any foam formation if possible. After a waiting time TOTAL 100.00 of ten minutes, so that any air bubbles formed during the filling could migrate to the surface and thus not falsify the I0082. The foam behavior of this composition 1 is shown in volume, 250 ml of the sample being investigated was drawn FIG 1. into the measuring space and measured. 0076. With a rotor speed of 2000 rpm, the sample being measured in the measuring space was subjected to five rotor Composition cycles of 20 seconds each to create the foam. Between rotor Ingredient in wt.% cycles there was a pause of around 15 seconds. 1 Lidocaine hydrochloride 1O.OO 0077. By means of the sensors described in DE 19949 2 Propylene glycol 1O.OO 922, which automatically and continuously scanned the foam US 2016/0022579 A1 Jan. 28, 2016 13

-continued -continued Composition Composition Ingredient in wt.% Ingredient in wt.% 3 2-Propanol 11.00 9 Polysorbate 80 13.00 4 Phospholipid foaming agent A 1O.OO 10 Ultrapure water 48.52 5 Sodium dihydrogen phosphate dihydrate O.12 6 Disodium hydrogen phosphate dodecahydrate, cryst. O.66 TOTAL 100.00 7 Sodium hydroxide 20% w/w 4.OO 8 Peppermint oil O.15 9 Ultrapure water S4O7 I0086. The foam behavior of this composition 5 is shown in FIG.S. TOTAL 1OOOO I0087 Twenty subjects (11 female, 9 male) suffering from fungal disease between the toes and also partly on the toenails 0083. The foam behavior of this composition 2 is shown in had the fungally attacked regions of the left foot treated twice FIG 2. daily with a foam prepared by the above-described SITA measurement method. The treatment was done in that the ailing area was covered with a foam layer around 0.5 to 1 cm Composition thick and then this foam was manually rubbed in. The total Ingredient in wt.% treatment time lasted up to 14 days. 1 Prednicarbate O.10 I0088. The ailing area of the right foot was treated with a 2 Propylene glycol 1S.OO composition 5, identical in ingredients, while this composi 3 2-Propanol 9.35 4 Phospholipid foaming agent B S.OO tion 5 was foamed by means of a “M3 mini foamer from 5 Sodium dihydrogen phosphate dihydrate OSO Rexam/Airspray immediately prior to application. 6 Disodium hydrogen phosphate dodecahydrate, cryst. 1.14 7 Sodium hydroxide 10% w/w 1.00 I0089 Regardless of which foam had been applied to the 8 Tegosoft GC 8.60 ailing areas, 16 Subjects reported a direct decrease in itching 9 Ultrapure water 59.31 already after the first application of the particular foam. Two other subjects reported this decrease in itching after a two TOTAL 1OOOO time application, and the remaining two Subjects reported the decrease in itching after a four-time application. 0084. The foam behavior of this composition 3 is shown in 0090. In ten subjects, the fungal infections were elimi FIG. 3. nated after a total treatment time of eight days, in six subjects the healing time was eleven days, and in four Subjects the healing time was 14 days. It is to be noted that the latter four Composition subjects were the most heavily affected by the fungal infec Ingredient in wt.% tion. No subject could find a difference between the foam 1 Diclofenac 4.OOO created by the SITA measurement method and the foam pro 2 1,2-propane diol 1S.OOO duced by the “M3 mini foamer. 3 2-Propanol 10.2SO 4 L (+) aScorbylpalmitate O.O2O 5 Phospholipid foaming agent A 2O.OOO Examples 6 to 8 6 Sodium dihydrogen phosphate dihydrate, ultrapure O. 120 7 Disodium hydrogen phosphate dodecahydrate, O.660 ultrapure 0091. In order to investigate the influence of the concen 8 EDTA, Titriplex III O.040 tration of active ingredient on the foam formation, the follow 9 Ultrapure water 49.710 ing compositions 6 to 18 were prepared and investigated in 10 Peppermint oil O.200 regard to the concentrations of active ingredient diclofenac. TOTAL 100.00 Composition Ingredient in wt.% 0085. The foam behavior of this composition 4 is shown in 1 Diclofenac 1.OOO FIG. 4. 2 Propylene glycol 1S.OOO 3 2-Propanol 10.2SO 4 Ascorbylpalmitate O.O2O Composition 5 Phospholipid foaming agent A 13.330 Ingredient in wt.% 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 1 Clotrimazol O.S 7 Disodium hydrogen phosphate O660 2 Propylene glycol 2O.OO dodecahydrate, cryst. 3 2-Propanol 8.00 8 EDTA O.040 4 Phospholipid foaming agent A 8.00 9 Ultrapure water 59.380 5 Sodium dihydrogen phosphate dihydrate O.12 10 Peppermint oil, rectified O.200 6 Disodium hydrogen phosphate dodecahydrate, cryst. O.66 7 Sodium hydroxide 20% w/w 1.00 TOTAL 1OOOO 8 Peppermint oil O.20 US 2016/0022579 A1 Jan. 28, 2016 14

0092. The foam behavior of this composition 6 is shown in -continued FIG. 6. Composition Ingredient in wt.%

Composition 8 EDTA O.040 Ingredient in wt.% 9 Ultrapure water 67.710 1 Diclofenac 2.OOO 10 Peppermint oil, rectified O.200 2 Propylene glycol 1S.OOO 3 2-Propanol 10.2SO TOTAL 1OOOO 4 Ascorbylpalmitate O.O20 5 Phospholipid foaming agent A 13.330 6 Sodium dihydrogen phosphate O.12O dihydrate 0097. The foam behavior of this composition 9 is shown in 7 Disodium hydrogen phosphate O.660 FIG. 9. dodecahydrate, cryst. 8 EDTA O.O40 9 Ultrapure water 58.380 Composition 10 Peppermint oil, rectified O.200 Ingredient in wt.% TOTAL 100.00 1 Diclofenac 4.OOO 2 1,2-propane diol 1S.OOO 3 2-Propanol 10.2SO 0093. The foam behavior of this composition 7 is shown in 4 L (+) ascorbylpalmitate O.O2O FIG. 7. 5 Phospholipid foaming agent A S.OOO 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 7 Disodium hydrogen phosphate O660 Composition dodecahydrate, ultrapure Ingredient in wt.% 8 EDTA O.040 9 Ultrapure water 64.710 1 Diclofenac 8.OOO 10 Peppermint oil, rectified O.200 2 Propylene glycol 1S.OOO 3 2-Propanol 10.2SO TOTAL 1OOOO 4 Ascorbylpalmitate O.O20 5 Phospholipid foaming agent A 13.330 6 Sodium dihydrogen phosphate O.12O dihydrate 0098. The foam behavior of this composition 10 is shown 7 Disodium hydrogen phosphate O.660 in FIG. 10. dodecahydrate, cryst. 8 EDTA, Titriplex III O.O40 9 Ultrapure water S2.380 10 Peppermint oil, rectified O.200 Composition Ingredient in wt.% TOTAL 100.00 1 Diclofenac 4.OOO 2 1,2-propane diol 1S.OOO 3 2-Propanol 10.2SO 0094. The foam behavior of this composition 8 is shown in 4 L (+) ascorbylpalmitate O.O2O FIG 8. 5 Phospholipid foaming agent A 2O.OOO 0095 Based on the comparison of the compositions 6 to 8 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure and the corresponding FIGS. 6 to 8, one can say that the foam 7 Disodium hydrogen phosphate O660 Volume increases with practically unchanged foam stability dodecahydrate, ultrapure as the concentration of active ingredient increases. 8 EDTA, Titriplex III O.040 9 Ultrapure water 49.710 Examples 9 to 11 10 Peppermint oil, rectified O.200 0096. In order to investigate the influence of the concen TOTAL 1OOOO tration of phospholipid foaming agent on the foam formation, the following compositions 9 to 11 were prepared and inves tigated in regard to the concentration of phospholipid foam 0099. The foam behavior of this composition 11 is shown ing agent. in FIG. 11. 0100 Based on the comparison of the compositions 9 to 11 and the corresponding FIGS. 9 to 11, one can say that the Composition foam Volume decreases with practically unchanged foam sta Ingredient in wt.% bility as the concentration of the phospholipid foaming agent 1 Diclofenac 4.OOO increases. 2 1,2-propane diol 1S.OOO 3 2-Propanol 10.2SO 4 L (+) ascorbylpalmitate O.O2O Examples 12 to 14 5 Phospholipid foaming agent A 2.OOO 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 0101. In order to investigate the influence of the concen 7 Disodium hydrogen phosphate O660 tration of isopropanol on the foam formation, the following dodecahydrate, ultrapure compositions 12 to 14 were prepared and investigated in regard to the concentration of isopropanol. US 2016/0022579 A1 Jan. 28, 2016

Examples 15 to 17 Ingredient Cspon iti 0106. In order to investigate the influence of the concen tration of propylene glycol on the foam formation, the fol 1 Diclofenac 4.OOO lowing compositions 15 to 17 were prepared, differing in 23 2-PropanolPropylene glycol 1S.OOOS.OOO terms of the concentration of propylenepropvlene glycol.glvcol 4 Ascorbylpalmitate O.O20 5 Phospholipid foaming agent A 13.330 6 Sodium dihydrogen phosphate O.12O Composition dihydrate Ingredient in wt.% 7 Disodium hydrogen phosphate O.660 dodecahydrate, cryst. 1 Diclofenac 4.OOO 8 EDTA O.O40 2 1,2-propane diol S.OOO 9 Ultrapure water 61.63O 3 2-Propanol 10.2SO 10 Peppermint oil, rectified O.200 4 L (+) ascorbylpalmitate O.O2O 5 Phospholipid foaming agent A 13.330 TOTAL 100.00 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 7 Disodium hydrogen phosphate O660 0102 The foam behavior of this composition 12 is shown dodecahydrate, ultrapure in FIG. 12. 8 EDTA O.040 9 Ultrapure water 66.380 10 Peppermint oil, rectified O.200 Composition TOTAL 1OOOO Ingredient in wt.% 1 Diclofenac 4.OOO 0107 The foam behavior of this compositionp 15 is shown 2 Propylene glycol 1S.OOO in FIG. 15 3 2-Propanol 10.2SO . . Y.1 4 Ascorbylpalmitate O.O20 5 Phospholipid foaming agent A 13.330 6 Sodium dihydrogen phosphate O.12O Composition dihydrate Ingredient in wt.% 7 Disodium hydrogen phosphate O.660 dodecahydrate, cryst. 1 Diclofenac 4.OOO 8 EDTA O.O40 2 1,2-propane diol 1O.OOO 9 Ultrapure water 56.630 3 2-Propanol 10.2SO 10 Peppermint oil, rectified O.200 4 L (+) ascorbylpalmitate O.O2O 5 Phospholipid foaming agent A 13.330 TOTAL 100.00 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 7 Disodium hydrogen phosphate O660 0103) The foam behavior of this composition 13 is shown 8 ilydrate ultrapure O.040 in FIG. 13. 9 Ultrapure water 61.380 10 Peppermint oil, rectified O.200 Composition TOTAL 1OOOO Ingredient in wt.% 1 Diclofenac 4.OOO 0108. The foam behavior of this compositionp 16 is shown 2 Propylene glycol 1S.OOO in FIG. 16. 3 2-Propanol 2O.OOO 4 Ascorbylpalmitate O.O20 5 Phospholipid foaming agent A 13.330 6 Sodium dihydrogen phosphate O.12O Composition dihydrate Ingredient in wt.% 7 Disodium hydrogen phosphate O.660 1 Diclof 4.OOO dodecahydrate, cryst. ICOCl3C 8 EDTA O.O40 2 1,2-propane diol 2O.OOO 9 Ultrapure water 46.63O 3 2-Propanol 10.2SO 10 Peppermint oil, rectified O.200 4 L (+) ascorbylpalmitate O.O2O 5 Phospholipid foaming agent A 13.330 TOTAL 100.00 6 Sodium dihydrogen phosphate O.120 dihydrate, ultrapure 7 Disodium hydrogen phosphate O660 0104. The foam behavior of this composition 14 is shown 8 ilydrate ultrapure O.040 in FIG. 14. 9 Ultrapure water 51.380 0105 Based on the comparison of the compositions 12 to 10 Peppermint oil, rectified O.200 14 and the corresponding FIGS. 12 to 14, one can say that the TOTAL 1OOOO foam Volume increases as a function of the concentration of isopropanol with rising concentration of isopropanol from 5 wt.% to 10 wt.% and then decreases again in the range of 10 0109 The foam behavior of this composition 17 is shown wt.% to 20 wt.%, so that no stable foam is formed at a in FIG. 17. concentration of 20 wt.% of isopropanol. The slight foam 0110 Based on the comparison of the compositions 15 to volume shown initially in FIG. 14 should be disregarded. 17 and the corresponding FIGS. 15 to 17, one can say that the US 2016/0022579 A1 Jan. 28, 2016

concentration of propylene glycol has little or only a very used were produced by means of the above-described SITA slight influence on the foam volume and the foam stability. measurement method, as well as the “M3 minifoamer of Rexam/Airspray, based on the same starting compositions. Example 18 0117. The artificial UV erythemas were created at 16 test 0111. In a comparison investigation on 14 subjects (8 fields (each one 2x2 cm) on the back, 4 test fields to the left female, 6 male) with pronounced acne in the facial region, the and right of the spinal column, as well as 4 test fields in the Subjects were treated twice daily (morning and evening) with upper and lower region of the back. The 8 upper test fields a foam that was made from a composition whose ingredients were exposed to a UV dose of 1.5xMED and the lower test are quantified in the following table per composition 18. fields with 2.5xMED. 0118. After the UV exposure, ECG rings with an inner diameter of 16 mm were glued to the centers of the UV Composition exposed test fields. The untreated fields were likewise marked Ingredient in wt.% with ECG rings. The distance between the test fields was around 3 cm. 1 Erythromycin 1...SO 2 Propylene glycol 1S.OO 0119) Next, around 10-15 minutes from the end of the UV 3 2-Propanol 9.35 exposure, a dose of 25ug foam according to a random list was 4 Phospholipid foaming agent B 8.00 applied in the ECG rings and evenly distributed using a round 5 Sodium dihydrogen O.SO phosphate-dihydrate spatula. The foam behavior of composition 19 c) (ketoprofen 6 Disodium hydrogen 1.14 free composition) is shown in FIG. 19. phosphate-dodecahydrate cryst. I0120 Evaluation of the differences was done by the opti 7 Sodium hydroxide 10% w/w 1.00 cal examination of a dermatologist. This was based on the 8 Tegosoft GC 7.70 internationally recognized visual evaluation method of 0-no 9 Ultrapure water 55.81 visible erythema to 4-intensive erythema for the untreated TOTAL 100.00 surface and the evaluation -1 =intensive erythema to 3-com pletely suppressed erythema for the irradiated and treated areas. Checks were done after 2, 3, 4, 5, 6 and 8 hours on the The foaming behavior of this composition 18 is shown in FIG. same day as the application. 18. I0121 Between the foams produced according to the SITA 0112 The treatment was done per application with a measurement method and those using the “M3 minifoamer, defined amount of 0.4 mg foam per half of the face. The foam a slight difference for the active Substance, ketoprofen, was was applied directly to the area being treated and massaged in found only at one measurement time point: 6 hours. This by circular motions with 2 fingers. The total therapy time difference was not significant. Here, an erythema value of 2 amounted to 60 days. was found for the foam that was made according to the SITA 0113. Each time the left half of the face of each subject was measurement method and a value of 1 for the foam that was treated with the foam made by means of the above-described made by means of the “M3 minifoamer'. No other differ SITA measurement method and the right half of the face of ences could be found between the foams produced in different each subject by means of a foam made with an “M3 mini ways and containing the active Substance. foamer of Rexam/Airspray, both foams being prepared from I0122. In comparison with the ketoprofen-free composi composition 18. tion (c) and the untreated test fields, the foams containing 0114. The first success could already be determined for active substance showed distinct differences at 1.5 MED and both foams after 30 days application: the lesions on the left 2.5 MED in the final measurement after 8 hours. side of the face were reduced by around 19% and those of the (0123. Especially at 2.5 MED, a value of 1 was found for right half by around 21%. the foam containing diclofenac (slight Suppression of the 0115. At the final evaluation on day 60 of the investigation, erythema, easily identifiable), a value of 2 for the foam con a decrease inlesions by around 36% was found for the left half taining ketoprofen (distinct Suppression of the erythema but of the face and a decrease of around 34% for the right half of still visible) and a value of -1 for the ketoprofen-free foam the face. It was not possible to determine a significant differ (more pronounced erythema). The foam made from the com ence between the two halves of the face. None of the subjects position containing ketoprofen shows a clear therapeutic perceived the treatment to be unpleasant or reported painful Superiority over the foam containing diclofenac, the ketopro irritation of the treated areas. Neither could any differences be fen-free foam, and the untreated test fields. established in the toleration of the treatment between the two 0.124 All foams containing active Substance showed a halves of the face. good toleration. Only for the ketoprofen-free foam were 3 side effects found. Sample Embodiment 19 0.125. The phospholipid foaming agent A used above in 0116. In a double-blind, randomized and placebo-con examples 1 and 2, as well as 4 to 17, has the following trolled comparative study of 12 subjects (5 female, 7 male) we composition, with the following values referring to the dry investigated the efficacy of a) the above-described composi Substance. tion 10, containing 4% diclofenac-sodium, b) of the above described composition 1, containing 10% ketoprofen, and the Phosphatidylcholine efficacy of a ketoprofen-free composition, which was identi Lysophosphatidylcholine cal to composition 1 in terms of ingredients 2 to 9, this Phosphatidic acid ketoprofen-free composition having no ketoprofen and Phosphatidyl ethanolamine instead having 10 wt.% more water than composition 1, in the Other oily components treatment of an artificially induced UV erythema. All foams US 2016/0022579 A1 Jan. 28, 2016

-continued e. Varying the concentration of at least one of the pharma ceutically active agent, the isopropanol, the further Sol Acid number 2 vent, or the foaming agent; Peroxide number 6 f. repeating steps b through e until 250 ml of the liquid composition, after the mechanical creation of the foam, 0126 The phospholipid foaming agent B used above in has a foam density between 0.05 g/mland 0.8 g/ml, foam examples 3 and 18 has the following composition, with the volume of at least 400 ml and a foam stability wherein at following values referring to the dry Substance. least about 50% of the foam volume is still present after about 5 minutes at 25°C. 2. The method of claim 1, wherein the at least one further Phosphatidylcholine Solvent is chosen from the group consisting of water, a Lysophosphatidylcholine Tocopherol max. 0.3 wt.% monovalent alcohol, a polyalcohol, and mixtures thereof. Acid number 1 3. The method of claim 1, the pharmaceutical active ingre Peroxide number 5 dient is a further foaming agent. 4. The method of claim 1, wherein the liquid composition further comprises at least one of a complexing agent, a buffer, 0127. The above indicated peroxide number indicates the a thickening agent, an antioxidant and/or a stabilizer. millieduivalents of oxygen which are contained in 1000 g of 5. A foam applicator comprising: a sample (dry Substance). This value, after reacting the a liquid composition Suitable for topical use comprising: sample with potassium iodide in a mixture of chloroform and between 4 wt.% and 15 wt.% of a phospholipid foaming acetic acid, is determined by titrating the iodine produced in agent comprising 50 wt.% to 95 wt.% phosphatidyl this way with sodium thiosulfate and a potentiometric deter choline in relation to the dry substance of the phospho mination. lipid foaming agent, wherein the phosphatidylcholine 0128. The acid number indicates how many mg of potas has an acid number of at most 10, a peroxide number of sium hydroxide are needed to neutralize the free, nonesteri at most 10, and an oil concentration of at most 6 wt.%; fied fatty acids that are contained in 1 g of phospholipid 5 wt.% to 15 wt.% isopropanol, foaming agent (dry Substance). This value is determined by at least one further solvent; and titration of a corresponding dissolved sample with potassium a pharmaceutically acceptable active agent; wherein the hydroxide solution, using phenolphthalein as indicator. foam applicator mechanically foams the liquid compo sition without an additional propellant; and EQUIVALENTS wherein upon mechanical foaming of 250 ml of the liquid 0129. Those skilled in the art will recognize, or be able to composition results in a foam with a foam Volume of at ascertain using no more than routine experimentation, many least about 400 ml and a foam stability wherein at least equivalents to the specific embodiments of the invention about 50% of the foam volume is still present after about described herein. Such equivalents are intended to be encom 5 minutes at 25°C., as determined using a SITA foam passed by the following claims. measurement; and wherein the foam has a density of about 0.05 g/ml and about 0.8 g/ml. INCORPORATION BY REFERENCE 6. The foam of claim 10, wherein the foam volume is about 600 ml to about 1200 ml. 0130. The entire contents of all patents, published patent 7. The foam of claim 10, wherein at least about 50% of the applications, websites, and other references cited herein are foam volume is still present after about 10 minutes. hereby expressly incorporated herein in their entireties by 8. The foam of claim 10, wherein about 55% to about 85% reference. of the foam volume is still present after about 5 minutes after 1. A method for making a foamable liquid composition for being formed. topical use, comprising: 9. The foam of claim 10, wherein about 85% to about 100% a. providing a liquid composition comprising: of the foam is still present after about 10 minutes after being at least one pharmaceutically active agent, formed. 10. A foam suitable for topical use, formed by mechanical 5 wt.% to 15 wt.% isopropanol, foaming without use of an additional propellanta liquid com at least one further solvent, and position comprising: at least one systemically and/or topi at least one phospholipid foaming agent comprising 50 cally acting pharmaceutical active ingredient, 5 wt.% to 15 wt.% to 95 wt.% phosphatidylcholine, in relation to wt.% isopropanol, the dry Substance of the phospholipid foaming agent; at least one further solvent and and wherein the phosphatidyl choline has an acid between 4 wt.% and 15 wt.% of a phospholipid foaming number of at most 10, a peroxide number of at most agent comprising 50 wt.% to 95 wt.% phosphatidyl 10, and an oil concentration of at most 6 wt.%; choline in relation to the dry substance of the phospho b. mechanically creating a foam of the liquid composition; lipid foaming agent, wherein the phosphatidylcholine c. Scanning the foam Surface to determine the stability and has an acid number of at most 10, a peroxide number of the volume of the foam and thereby determining the at most 10, and an oil concentration of at most 6 wt.%. foam volume and the foam stability using a SITA mea wherein the foam so created by foaming 250 ml of the surement method without the use of a propellant; liquid composition has a foam volume of between 450 d. correlating the foam Volume and the foam stability as and 1400 ml, specified by the SITA measurement method with the wherein the foam stability has, after a dwell time of up to pharmaceutical properties of the foam; ten minutes between 55% and 100% of the foam volume US 2016/0022579 A1 Jan. 28, 2016 18

that was originally present immediately after the cre 15. The foam of claim 13, wherein the liquid composition ation of the foam, wherein both the foam volume and the comprises between 0.01 wt.% and 10 wt.% of at least one foam stability is determined by a standardized SITA antimycotic. foam measurement method, and wherein the foam has a 16. The foam of claim 13, wherein the liquid composition density of about 0.05 g/ml and about 0.8 g/ml. comprises at least one corticoid active ingredient in a concen tration between 0.1 wt.% and 5 wt.%. 11. The foam of claim 10, wherein the foam has a density 17. The foam of claim 10, wherein the liquid composition of about 0.15 g/ml and about 0.4 g/ml. comprises at least one topical anesthetic in a concentration 12. The foam of claim 10, wherein the further solvent is between 3 wt.% and 15 wt.%. selected from the group consisting of water, a monovalent 18. The foam of claim 10, wherein the liquid composition alcohol, a polyalcohol, and mixtures thereof. comprises an immunomodulator in a concentration between 0.03 wt.% and 0.1 wt.%. 13. The foam of claim 10, wherein the active ingredient is 19. The foam of claim 10, wherein the phospholipid foam selected from the group consisting of local anesthetics, anti ing agent comprises at most 15 wt.% of lyso-phosphatidyl mycotics, antibiotics, analgesics, nonsteroidal antirrheumat choline, at most 10 wt.% of phosphatidic acid and at most 10 ics, nonsteroidal anti-inflammatories, corticoids, immune wt.% of phosphatidyl ethanolamine. modulators and salts thereof. 20. The foam of claim 10, wherein the further solvent is 14. The foam of claim 13, wherein the liquid composition propylene glycol, and is present in the composition in a con comprises between 0.1 wt.% and 20 wt.% of at least one centration between 2 wt.% and 25 wt.%. analgesic. k k k k k